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ABSTRACT 
Lipocalin 2 (Lcn2) is a member of the lipocalin family, members of which are usually 
small extracellular proteins with the abilities of binding and transporting small hydrophobic 
molecules. Lcn2 was named neutrophil gelatinase-associated lipocalin (NGAL) in human, 
neu related lipocalin (NRL) in rat and SIP24, 24p3, uterocalin, and siderocalin in mouse. The 
expression level of Lcn2 in the mammary gland is very high during involution. Results in this 
thesis show that the expression of rat Lcn2 (NRL) is higher in primiparous rat mammary 
glands after 28 days of involution than its expression in age matched virgin (AMV) 
mammary glands. Parity is associated with a lower incidence of breast cancer. The 
population size of macrophages in primiparous mammary glands is also higher in parous 
glands. More immune surveillance provided by the larger number of macrophages in the 
mammary gland after involution may be one reason for the observed parity induced 
protection against breast cancer.  
The expression levels of Lcn2 and other inflammatory genes are induced in HC11 
cells, a mammary gland epithelial cell line, by mycoplasma infection or the mycoplasma 
membrane lipopeptide macrophage-activating lipopeptide-2 (MALP-2). Using the Lcn2 
promoter linked to a luciferase reporter plasmid, we investigated the mechanism by which 
MALP-2 regulates gene expression and demonstrated that it activates NFκB and C/EBP and 
induces IκBζ.  Reduction in IκBζ by RNAi reduced Lcn2 promoter activation by MALP-2. 
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CHAPTER 1.  GENERAL INTRODUCTION 
1.1  Dissertation Organization 
Chapter 1 is a general introduction covering the topics presented in this dissertation. 
A detailed review of Lcn2 is given first. Following is a review of human breast development 
and the relationship of pregnancy and breast cancer. A discussion of macrophages and 
mammary gland development is also included. Next, a review of mycoplasma and its 
membrane protein macrophage-activating lipopeptide-2 (MALP-2) is presented. The last part 
of the general introduction is a review of some aspects of inflammation. Chapter 2 is based 
on my finding of higher expression levels of Lcn2, and several other genes, in fully involuted 
mammary glands compared with age-matched virgin glands. The results also show that the 
population size of macrophages is higher in fully involuted mammary glands. In chapter 3, 
the results of the effect of mycoplasma and MALP-2 on mammary epithelial (HC11) cells are 
reported. In this section I show that Lcn2 expression by HC11 cells is induced by 
mycoplasma infection or by the mycoplasma membrane lipopeptide macrophage-activating 
lipopeptide-2 (MALP-2). MALP-2 is shown to regulate Lcn2 expression by activating NFκB 
and C/EBP and inducing IκBζ.  A general discussion is given in Chapter 4. In the appendix, 
the work to develop a Lcn2 overexpressing mouse line is described. Thanks to people who 
have contributed to this thesis are given in the acknowledgment. 
 
1.2  Specific Aims and Significance 
Demonstration of a larger Macrophage Population Size and Up-Regulat-
ion of Lcn2 in The Fully Involuted Mammary Gland of Rat. 
Parity is a demonstrated strong protective factor for breast cancer. However the 
mechanism of parity induced protection against breast cancer is not clear and the purpose of 
this study was to investigate its mechanistic basis.  The study started with the hypothesis that 
inflammation was suppressed in the parous breast.  The initial analysis of the expression 
levels of genes that reflect the inflammatory condition of the tissue identified many genes 
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associated with macrophages that were elevated in primiparous breast tissue compared with 
mammary tissue from age-matched virgns. This initiated a study to determine whether there 
are more macrophages in the fully involuted rat mammary gland.  Such a finding would be 
reasonable because increased immune surveillance in the mammary gland by macrophages is 
a possible reason for protection against breast cancer.  Previous studies showed that the 
number of macrophages in the mouse mammary gland increases during early involution 
(Atabai et al., 2005; Lund et al., 1996; Stein et al., 2004). The results of a previously 
published microarray study suggested that there are more macrophages in the mouse 
mammary gland after the mammary gland has completed its involution compared with age-
matched virgin glands (D'Cruz et al., 2002). However, there was no evidence to demonstrate 
the basis of this difference. The results from this study, in which the macrophage population 
was assessed by real-time RT-PCR and immunochemical staining, showed that the number 
of macrophages is higher in fully involuted mammary glands of rats compared with in age-
matched virgins. The results also demonstrate that the level of Lcn2 expression is higher in 
mammary glands after involution. Lcn2 is expressed by epithelial and hematopoietic cell 
types and has been shown to induce apoptosis in neutrophils but not in macrophages. The 
persistently high expression of Lcn2 in involuted mammary glands may be one reason that 
more macrophages but not neutrophils remain in the gland after involution is complete. In 
summary, I found that the number of macrophages is higher after complete involution of the 
primiparous rat mammary gland compared to the virgin gland. I propose that the resulting 
increased immune surveillance in the mammary gland may play a role in protecting the 
parous gland against breast cancer. 
The Effect of Mycoplasma Infection or MALP-2 on HC11 Cells 
Mycoplasma infection causes inflammation of epithelial tissues in vivo and is a 
frequent problem in cell cultures. It is important to understand how mycoplasma infection 
might influence epithelial cell signaling and gene expression. The expression levels of three 
genes encoding proteins secreted during the innate immune response (Lcn2, IL-6 and TNFα) 
were found elevated in mycoplasma-infected mammary epithelial (HC11) cells.  Expression 
of these genes was also increased in response to MALP-2, a mycoplasmal membrane 
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lipopeptide. MALP-2 activates NFκB and C/EBP and induces IκBζ to activate the Lcn2 
promoter. Reduction of IκBζ by RNAi reduced Lcn2 promoter activation by MALP-2.  Thus, 
mycoplasma contamination can significantly change the gene expression pattern of epithelial 
cells, creating a condition that resembles their activation during the innate immune response. 
 
1.3  The Lipocalin Family 
Pervaiz and Brew first proposed the grouping and name of the lipocalin family. They 
used the name “lipocalin” to describe and emphasize the common ability of this group 
proteins to bind lipophilic molecules. As more members were identified, the lipocalin family 
was found to be large and diverse (Pervaiz and Brew, 1985; Pervaiz and Brew, 1987). 
Lipocalins are found in various species including vertebrate and invertebrate animals, plants, 
insects and even bacteria. Lipocalin family members are usually small (160-180 amino acids) 
extracellular proteins. The overall amino acid sequence similarity of members may be low, 
sometimes even lower than the nominal threshold of 20%. However, lipocalins share short 
conserved sequence motifs. Flower identified three such motifs (also called structurally 
conserved regions, SCRs) among lipocalins. Most lipocalins, which are also called kernel 
lipocalins, such as retinol binding protein, β-lactoglobin, and lipocalin 2, share all three SCRs. 
Other lipocalins, such as the odorant-binding protein, share only one or two SCRs and they 
are called outlier lipocalins, (Flower et al., 1993; Flower et al., 2000). Despite the low amino 
acid sequence conservation, lipocalins share a common tertiary structure, which is a 
symmetric hydrogen bonded β-barrel formed by a single eight stranded anti-parallel β-sheet. 
The cup-shaped interior, which forms a ligand-binding site, is usually lined with hydrophobic 
amino acid residues. It has an elliptical shape in cross-section (Flower et al., 2000; Kjeldsen 
et al., 1996) [Fig. 1]. 
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Fig. 1 
Figure 1. Structure of the lipocalin fold. (Reprinted from (Flower et al., 2000), Copyright (2000), 
with permission from Elsevier and with legend taken from the same article) 
A) An unwound view of the lipocalin fold orthogonal to the axis of the barrel. The nine β-strands of 
the antiparallel β-sheet are shown as arrows and labelled A-I. The C-terminal α-helix A1 and N-
terminal 310 like helix are also marked. Connecting loops are shown as solid lines and labelled L1-L7. 
A pair of dotted lines indicates the hydrogen-bonded connection of two strands. One end of the 
lipocalin L-barrel has four loops (L1, L3, L5, and L7); the opening of the internal ligand-binding site 
is here and so is called the Open end of the molecule. The other end has three L-hairpin loops (L2, L4 
and L6); the N-terminal polypeptide chain crosses this end of the barrel to enter strand A via a 
conserved 310 helix closing this end of the barrel: the Closed end of the molecule. Those parts that 
form the three main structurally, and sequence, conserved regions (SCRs) of the fold (SCRl, SCR2, 
and SCR3) are marked as heavy boxes. SCR3 corresponds closely with the sequence conserved region 
rather than the structurally conserved region.  
B) A schematic or ribbon drawing of the lipocalin fold. The structure shown is a prototypical, rather 
than an actual, structure. The nine conserved β-strands, the closed β-barrel, and the N-terminal and 
C-terminal helices are shown (see A above). Loops L1 and L6 are also marked. The size of the ligand 
binding ultrasite is represented by a collection of atoms, in a purple space-filling depiction, 
representing the structural overlay of a variety of lipocalin ligands which include retinol, 
retinoic acid, haem, and bilin. β-Strands are shown as smoothly curving arrows textured as grey 
granite, α-helices as golden spiral ribbons, and loops as silver cords. Figure generated using ALTER 
and POVRAY  
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The common cup-shape structure of lipocalins, which forms a putative binding site 
composed of both an internal cavity and an external scaffold which is the β-barrel, gives one 
an impression that they might have the ability to bind something. As a matter of fact, one 
common property shared by lipocalin proteins is their molecular binding properties. 
Lipocalins can bind small, usually hydrophobic molecules in the binding site. One example 
would be plasma retinol binding protein that can bind all-trans-retinol, retinal, or retinoic 
acid (Kanai et al., 1968; Newcomer and Ong, 2000; Ronne et al., 1983). Lipocalins may form 
covalent or non-covalent complexes with other macromolecules. For example, human 
neutrophil gelatinase-associated lipocalin (NGAL), the human lipocalin 2, links with 
neutrophil gelatinase via a covalent bond between these two molecules (Kjeldsen et al., 
1993). Another capability of lipocalins is that they can bind specific cell surface receptors. 
Sometimes, one lipocalin protein binds a specific receptor, for example, retinol binding 
protein binds its specific cell surface receptor and lipocalin 1 binds LIMR (Lcn1 interacting 
membrane receptor). Sometimes several lipocalins can bind the same receptor, for example, 
retinol binding protein (RBP), α-1-microglobulin (A1M), mouse major urinary protein 
(MUP), odorant-binding proteins (OBP) and NGAL can bind megalin, a type I 
transmembrane protein (Flower, 2000; Hvidberg et al., 2005; Leheste et al., 1999; Wojnar et 
al., 2001). 
Although lipocalins were once classified as transport proteins because of their 
abilities of binding small hydrophobic molecules and cell surface receptors, more functions 
of lipocalins are recognized beyond transport. Members of the lipocalin family only share a 
limited similarity at the amino acid sequence level and have diverse functions, such as 
cryptic coloration (lepidopteron and crustacean lipocalins), modulation of cell growth and 
metabolism (apolipoprotein D, α1-microglobulin), regulation of the immune response (α1-
microglobulin, glycodelin), smell reception (odorant-binding protein) and animal behaviors 
(α2-urinary globulin, major urinary protein) (Akerstrom et al., 2000; Flower, 1996; Flower et 
al., 2000; Kjeldsen et al., 2000).  
Lipocalins have also been used as biomarkers for some diseases such as inflammatory 
diseases, cancer, and lipid disorders. They were demonstrated to have potential clinical 
applications (Xu and Venge, 2000). For example, prostaglandin D synthase, which is the 
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only lipocalin that has enzyme activity, has been identified to be a potential marker for brain 
tumors, renal insufficiency and seminal plasma fertility (Diamandis et al., 1999; Peitsch and 
Boguski, 1991). Another example is that the α1-microglobulin has been used as a marker for 
renal tubular injury (Weber and Verwiebe, 1992). 
 
1.4  Lipocalin 2 
Lipocalin 2 is member of the lipocalin family and has been identified in human 
(neutrophil gelatinase-associated lipocalin: NGAL or human neutrophil lipocalin: HNL), rat 
(neu related lipocalin, NRL), mouse (superinducible protein 24KDa: SIP24, 24p3, uterocalin,, 
or siderocalin) and chicken (Extracellular Fatty Acid Binding Protein: EX-FABP).  
1.4.1 Name, Sequence and Structure 
Mouse lipocalin 2 has 200 amino acid residues including the signal peptide (180 
without the signal peptide). Mouse Lcn2 was first described as a growth factor induced and 
superinducible protein (SIP24) produced by mouse 3T3 cells (Nilsen-Hamilton et al., 1982). 
It was discovered again as an induced gene (24p3) in mouse kidney cells infected by SV40 or 
polyoma virus (Hraba-Renevey et al., 1989). Flower et al. did the protein sequence analysis 
and they identified the 24p3 protein as a member of lipocalin family by searching conserved 
sequence motifs (Flower et al., 1991). During pregnancy Lcn2 expression in the mouse 
uterus increases massively immediately before and peaks immediately after delivery (Liu et 
al., 1997). In fact, its expression in the uterus around parturition is even higher than its 
expression in the liver during the acute phase response and that is why it was also named as 
uterocalin (Liu et al., 1997). The human Lcn2, which was named neutrophil gelatinase-
associated lipocalin (NGAL), has 198 amino acid residues with the signal peptide (178 
without the signal peptide). It was co-purified with neutrophil gelatinase because a small 
fraction of NGAL formed a covalent complex with gelatinase. However, most NGAL exists 
as a monomer or a homodimer and colocalizes with lactoferrin in the neutrophil granules 
(Kjeldsen et al., 1994; Kjeldsen et al., 1993). The protein was purified as a dimer 
independently by another group and named as human neutrophil lipocalin (HNL). They 
found that the protein is associated with secondary granules in neutrophil and the cells 
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released about 50% of the total cellular NGAL content when exposed to serum-opsonized 
particles (Xu et al., 1994). Among the sequenced Lcn2 orthologs, NGAL is the only one that 
forms a covalent bond with itself or other molecules. The reason is that Lcn2 from mouse 
and rat have only two cysteine residues that form a disulfide bond within the molecule, while 
NGAL has three cysteine residues that leave a free cysteine residue after forming the 
disulfide bond. The rat version of Lcn2, which has 198 amino acid with the signal peptide 
(178 without the signal peptide), was named neu related lipocalin (NRL) due to the 12 fold 
overexpression of the protein in neu (HER2/c-erbB-2) induced breast cancers but not in ras 
or chemically induced carcinomas (Stoesz and Gould, 1995). Lcn2 undergoes post 
translational modification, for example, N-glycosylation was found in the human and mouse 
Lcn2 proteins (Davis et al., 1991b; Kjeldsen et al., 1993).  
Chicken Lcn2 was first described as a 20K transformation sensitive protein secreted 
by quiescent chicken embryo fibroblasts (Bedard et al., 1989). It was not identified as a 
lipocalin at that time. Later, another group proposed the name of Extracellular Fatty Acid 
Binding Protein (EX-FABP), because it binds long-chain unsaturated fatty acids (Cancedda 
et al., 1996). EX-FABP is a monomer and has a potential glycosylation site, but no 
glycosylation was found (Descalzi Cancedda et al., 2000).  
In 2000, Goetz et al. published the NGAL crystal structure. They had three 
independent NGAL structures: one from dimeric NGAL and two from monomeric NGAL. 
Although the pH and salt concentration they used for crystallization of the three structures 
was different, the three NGAL structures were essentially identical. Their results confirmed 
that NGAL shares the typical lipocalin conserved eight-stranded β-barrel fold, a short 310 
helix (residues 24-28) and a four-turn α-helix (residues 145-160). However, the NGAL calyx 
is larger, wider and more open when compared with other lipocalin structures. Another 
feature of the NGAL calyx is that it is lined with more polar and positively charged residues 
than typical lipocalins [Fig 2]. Both the dimeric structure and monomeric structure contain a 
disulfide linkage between cysteines 76 and 175. In the dimeric structure, there is a disulfide 
bond between cysteine 87 on each monomer to form the dimer. This disulfide bond is unique 
for NGAL and not seen in uterocalin or NRL. However, the presence of this disulfide bond 
does not affect the NGAL crystal structure (Goetz et al., 2000). There is no published crystal 
 8 
 
structure for the mouse or rat versions of Lcn2. But it is reasonable to conclude that 
uterocalin and NRL have very similar structures to NGAL because Lcn2 proteins from 
different species share a very high sequence homology.  For example, NGAL and uterocalin 
are 62% identical at the amino acid level. NGAL and NRL are 64% identical, uterocalin and 
NRL are 80% identical [Fig 3.]. In this introduction the following terms will be used to refer 
to the Lcn2s of different species: uterocalin for mouse Lcn2, NGAL for human Lcn2, NRL 
for rat Lcn2, and EX-FABP for chicken Lcn2. 
 
        
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    Fig. 2 
 
Fig. 3  
Figure 3. Alignment of NGAl, NRL and Uterocalin . 
Protein sequences were obtained from the NCBI website. The alignment were done with the 
software of Vector NTI . 
Figure 2. NGAL Crystal Structure. (Reprinted from 
(Goetz et al., 2002), Copyright (2002), with permission 
from Elsevier and with legend taken from the same 
article )  
The 3.4 Å native anomalous difference electron density 
map is shown contoured at 3.0σ (red) and 5.5σ (dark 
red) superimposed on a ribbon representation of the 
NGAL structure and colored by secondary structure 
(helices, yellow; strands, green; coil, blue). 
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1.4.2  Lcn2 Ligands and Receptor 
The barrel shape of the lipocalin easily leads to the idea that it has binding capability. 
Many proposed ligands of Lcn2 have been reported. Uterocalin can form a complex with an 
N-formyl peptide (FMLF) with a micro molar KD. The same group showed that uterocalin 
can bind cholesteryl oleate, oleic acid, retinol, or retinoic acid at pH 7.4 with micro molar 
association constants. Uterocalin was reported to undergo a considerable conformation 
change in forming the protein-ligand complex (Chu et al., 1997; Chu et al., 1998). However, 
others found that fMLF and other proposed fatty acid ligands do not bind to NGAL (Bratt et 
al., 1999; Goetz et al., 2000). FMLF was also shown not to fit into the n-capric acid (NCA) 
binding site in the NGAL calyx (Goetz et al., 2000).  NCA co-purified with NGAL but it was 
found that the shape and chemical properties of NCA did not match the NGAL binding 
pocket, which makes it unlikely to be a NGAL ligand. This group proposed that a 
macromolecule, such as a small protein, might be the preferred NGAL ligand because the 
NGAL calyx is large enough (Goetz et al., 2000; Kjeldsen et al., 2000). Later, they identified 
the phenolate/catecholate-type enterobacterial ferric siderophore (enterobactin, ENT), a low 
molecular weight and ferric-specific chelator, as a ligand of NGAL (Goetz et al., 2002). The 
catecholate-type siderophore is one of the two types of siderophores secreted by bacteria (the 
other type is aerobactin, a hydroxamate-type siderophore). Enterobactin has the highest 
affinity for Fe3+ (KD=10-49 M).  The binding of NGAL and the Fe3+ enterobactin is tight and 
specific, with a KD of 0.41 ± 0.11 nM  The stoichiometry of NGAL:siderophore:Fe is 1:1:1 
(Goetz et al., 2002). NGAL also binds carboxymycobactins, which are soluble siderophores 
of mycobacteria (Holmes et al., 2005). Uterocalin also binds enterobactin with a KD of 0.43 
nM as measured by a fluorescence quenching assay. This is consistent with its structure and 
high degree of sequence identity to NGAL (Fischbach et al., 2006; Flo et al., 2004).  
Chicken Lcn2 was named EX-FABP because it was reported as the first extracellular 
protein that has the ability to selectively bind and transport fatty acids in extracellular fluids 
and blood. EX-FABP binds long-chain unsaturated fatty acids, such as oleic, linoleic, and 
arachidonic acid, with 0.2 nM dissociation constant (Cancedda et al., 1996).  
It was long suspected that there are receptor(s) for Lcn2 on the cell surface. Megalin, 
which belongs to low density lipoprotein receptor family, was identified as a NGAL receptor 
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(Hvidberg et al., 2005). Megalin is one of the largest human proteins. As a type I 
transmembrane protein, it has a single membrane-crossing region and has 4398 amino acid 
residues in its extracellular region. The extracellular region has 36 low density lipoprotein 
receptor ligand binding repeats. Its cytoplasmic domain contains two signals for coated pit-
mediated internalization and SH2 and SH3 recognition sites. Megalin binds apo-NGAL 
(NGAL without siderophore) with high affinity (KD=~60 nM), and the LDL-receptor type-A 
repeats of megalin are involved in the binding. The siderophore–bound NGAL has a similar 
affinity with megalin (Flower, 2000; Hvidberg et al., 2005). Devireddy et al. identified a 
potential uterocalin receptor with 12 putative transmembrane helices that mediates cell 
internalization of uterocalin. This receptor has two forms: long form (60 kDa) and short form 
(30 kDa) due to alternative splicing. The long form of the receptor is widely expressed in 
murine tissues. However, no purified protein, western blot, or binding data of uterocalin with 
the receptor was reported (Devireddy et al., 2005).  
1.4.3 Lcn2 Expression and Regulation 
Lcn2 is expressed in many tissues. In the mouse, basal level uterocalin expression is 
high in the mammary gland and the uterus. Uterocalin expression in the mouse uterus is 
mainly in the luminal and glandular epithelial cells of the endometrium (Huang et al., 1999; 
Ryon et al., 2002). The expression of uterocalin is even higher in both mammary gland and 
uterus during involution. Ryon et al. estimated that 0.2 to 0.5% of the total extractable 
protein from the mammary gland and uterus is uterocalin (Ryon et al., 2002). The expression 
of uterocalin is also detected in mouse liver, spleen, epididymis, testis and lung (Chu et al., 
2000; Garay-Rojas et al., 1996; Liu and Nilsen-Hamilton, 1995).  
In rats, high expression of Lcn2 was detected in Neu-induced breast cancer, which is 
the reason for its being named NRL (Stoesz and Gould, 1995). NRL also shows high 
expression in prehypertrophic chondrocytes in rat embryos. By using immunohistochemistry, 
NRL was localized to the forming skeletal muscle fibers and to the myocardium of the 
developing heart (Zerega et al., 2000). 
In the human, NGAL expression is detected in the normal human mammary gland 
and shows a heterogeneous expression pattern in primary breast cancer patients. However, 
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NGAL expression in human breast cancer is not associated with HER2/neu activation (Stoesz 
et al., 1998). In the bone marrow cells of myelocytes/metamylocytes, NGAL is synthesized 
during a narrow window of maturation of granulocyte precursors. The authors proposed and 
provided evidence that the reason for NGAL targeting to the secondary granule is the timing 
of NGAL biosynthesis rather than individual sorting information presented by the protein 
(Borregaard et al., 1995; Le Cabec et al., 1996). NGAL is almost undetectable in normal 
colon epithelial cells. But its expression is up-regulated in colon epithelial cells in colorectal 
neoplasia or inflammatory diseases (Nielsen et al., 1996). NGAL expression is also detected 
in normal lung, trachea and other tissues (Cowland and Borregaard, 1997). 
EX-FABP was also suggested as a stress protein with physiological expression in 
tissues with active remodeling or in tissues with an acute phase response due to a 
pathological condition (Cermelli et al., 2000; Fiorella Descalzi et al., 2002). 
Lcn2 expression is regulated by growth factors, hormones and cytokines. In mouse, 
uterocalin expression in uterus is regulated by ovarian steroids during the natural estrous 
cycle with a much higher expression in the proestrus and estrus stages (Huang et al., 1999). 
In Balb/c 3T3 cells, uterocalin expression is induced by bFGF and EGF (Davis et al., 1991a; 
Nilsen-Hamilton et al., 1982). TNFα alone can induce uterocalin expression in Balb/c normal 
liver (BNL) cells, and there is a synergistic effect of uterocalin expression in BNL cells when 
the cells are treated with TNFα together with IL-6 (Liu and Nilsen-Hamilton, 1995). 
However, in A549 cells, NGAL expression is upregulated by IL-1β but not by TNFα 
(Cowland et al., 2003). NRL expression in rat hepatocytes is upregulated by IL-1β but not by 
IL-6 (Jayaraman et al., 2005). IGF-I and G-CSF induce a marked increase in expression of 
uterocalin in myeloid cells (32D and derived cells) (Liu et al., 2005). But in FL5.12 cells, the 
addition of IGF-I to the culture medium blocks the high uterocalin expression caused by IL-3 
deprivation (Devireddy et al., 2001). The different effects of IGF-I and other growth factors 
on uterocalin expression may due to the different cell types used in these experiments.   
Some transcription factor binding sites were identified in the Lcn2 promoter that are 
important to the regulation of its expression. For example, two glucocorticoid responsive 
core elements (GRE) were found in the 5'-flanking region in the uterocalin gene, and 
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glucocorticoids (dexamethasone, Dex) induce the expression of uterocalin dramatically 
(Garay-Rojas et al., 1996).  
A NF-κB site was identified as the important element in IL-1β induction of NGAL 
expression in A549 cells. Although TNFα also activates NF-κB, it alone did not induce 
NGAL expression in A549 cells, although it activated the expression of IL-8, a known target 
of TNFα and this function was used as positive control in the experiment. The authors 
proposed that IL-1β may induce or modulate another transcription factor besides NF-κB, 
which is important for activation of the NGAL promoter (Cowland et al., 2003).  
Regulation of uterocalin expression by cytokines has also been reported. Uterocalin 
expression was induced by IL-9 in murine T lymphomas and STAT3 was believed to be 
involved in the process (Orabona et al., 2001). In 32D derived cell lines, uterocalin 
expression is upregulated through a G-CSF activated signal transduction pathway. STAT3 is 
activated by G-CSFR in the process and is an important mediator of increased uterocalin 
expression (Wang et al., 2005). C/EBPα plays a critical role in STAT3 regulation of 
uterocalin expression (Numata et al., 2005; Wang et al., 2005). Uterocalin was also identified 
as a novel target of IL-17. Uterocalin is regulated synergistically by IL-17 and TNFα in a 
preosteoblast cell line MC3T3-E1 (Shen et al., 2005). The target elements of IL-17 in 
uterocalin transcriptional regulation are a NFκB site and a C/EBP site (Shen et al., 2006). 
Other C/EBPs are also important in NGAL expression. C/EBPε was demonstrated to play an 
important role in the sorting of NGAL in neutrophil secondary granules (Gombart et al., 
2003). In neuroblastoma cells, the uterocalin gene is a downstream target of C/EBPβ (Cortes-
Canteli et al., 2004). All these reports support that STAT3, C/EBPs and NFκB are important 
in the regulation of uterocalin expression. 
Other signal transduction pathways were also suggested to be involved in Lcn2 
expression regulation. A recent paper reported two independent pathways that regulate 
uterocalin expression: the Wnt pathway and iron. Activation of the Wnt path way led to 
decreased expression of Lcn2. The iron concentration in the cell did not change during this 
process. On the other hand, down-regulation of uterocalin expression was observed when 
iron was depleted from the cell culture medium. Uterocalin expression was induced when 
iron was added to the iron-deprived cells (Ziegler et al., 2007). Others showed that p38, a 
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member of the MAP kinase superfamily, mediates uterocalin expression in the chondrocyte 
MC615 cell line and that NFκB is activated in the process (Ulivi et al., 2006). 
1.4.4 Iron Delivery and Apoptosis 
Iron is important for the growth of bacteria. One of the strategies of bacteria to obtain 
their iron supply is to synthesize a wide variety of low-molecular-weight iron chelators called 
siderophores, which are synthesized, secreted and taken up again by many microorganisms 
when the microorganisms can not obtain sufficient soluble iron from their environment 
directly (Braun and Killmann, 1999). Enterobactin, a catecholate-type siderophore from E. 
coli, has the highest affinity for ferric iron. Lcn2 binds enterobactin after the body is invaded 
by E. coli and prevents E. coli from obtaining iron (Flo et al., 2004). Thus, Lcn2 is proposed 
as part of the innate immune system and works as a bacteriostatic agent via an antibacterial 
iron depletion strategy (Goetz et al., 2002). This hypothesis is supported by in vivo 
experiments, in which Lcn2 knockout mice showed much lower survival rates than wild type 
mice when injected with a strain of E coli that acquires iron from the host in an enterobactin-
dependent way. But the responses of Lcn2 deficient mice and wild-type mice were the same 
when they were injected with bacteria whose siderophore does not bind Lcn2 (Flo et al., 
2004).  
Kidney ischemia-reperfusion injury induces acute tubular necrosis (ATN) in the 
human. During this process, a significantly increased level of NGAL is detected in the serum 
and the urine. Uterocalin expression increases extensively in the mouse kidney ischemia-
reperfusion injury model and the injection of exogenous iron-loaded uterocalin 
(uterocalin:siderophore:Fe complex), but not uterocalin:siderophore complex or uterocalin 
itself, rescues the mouse proximal tubule from ATN. This indicates that the delivery of iron 
by uterocalin is the essential factor for the rescue. An iron-binding cofactor was also reported 
in urine samples from normal mice (Mori et al., 2005). Berger et al. also showed the Lcn2 
knock-out mice are more sensitive than wild type mice to E. coli infection, but they did not 
find that Lcn2 deficient mice showed any difference from wild type mice in their response to 
ischemia reperfusion injury (Berger et al., 2006). Lcn2 expression was detected in ureteric 
bud cells and it induces mesenchymal to epithelial conversion. The authors proposed that this 
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is caused by the ability of Lcn2 to bind and deliver iron to the cytoplasm, where iron 
activates or represses iron-responsive genes, in a pathway that differs from that of transferrin 
(Yang et al., 2002). Lcn2 delivery of ferric iron to mouse spermatozoa is also reported 
(Elangovan et al., 2004).  
Several papers reported that Lcn2 is involved in apoptosis as a proapoptotic factor. 
For example, uterocalin induced apoptosis in FL5.12 cells (Devireddy et al., 2001). IL-3 is 
very important for the culture of FL5.12 pro-B cells. When IL-3 was deprived from the 
culture medium, FL5.12 pro-B cells underwent apoptosis. Increased uterocalin transcription 
was associated with apoptosis. Conditioned medium containing uterocalin induced apoptosis 
in FL5.12 pro-B cell line and other cell lines. Recombinant uterocalin from E. coli also has 
this ability. Moreover, uterocalin antisense RNA or antibody can block this effect. All these 
results lead to the conclusion that uterocalin can induce apoptosis in certain cell types 
(Devireddy et al., 2001). The relation of Lcn2 and apoptosis has also been reported by other 
groups. Bong et al. reported that transient expression of uterocalin induces apoptosis in 
HC11 cell line, which is a mouse mammary epithelial cell line (Bong et al., 2004). High 
expression of uterocalin is detected in mouse erythroid progenitor cells and uterocalin 
induces apoptosis and inhibits differentiation of erythroid progenitor cells in cell culture 
experiments (Miharada et al., 2005). Mouse Bcr-Abl positive hematopoietic cells persistently 
express and secrete uterocalin, which induces apoptosis in Bcr-Abl negative but not Bcr-Abl 
positive cells (Lin et al., 2005). Lcn2 is secreted by inflammatory activated microglia and 
renders microglia more sensitive to apoptotic signals in an autocrine manner (Lee et al., 
2007). 
Lcn2 is also reported as a survival factor. MK886, a strong proapoptotic agent, 
simultaneous induces apoptosis in FL5.12 cells and uterocalin mRNA expression. It was 
assumed at first that the increased expression of uterocalin is an apoptotic mechanism of 
MK886. But later, the same group suggested that NGAL might be  actually a survival factor 
because overexpression of NGAL protects cells from apoptosis induced by phosphoinositide-
dependent kinase 1 (PDK1) inhibitors and NGAL antisera induces apoptosis in human MCF7 
and A549 cell lines with stable NGAL overexpression (Tong et al., 2003; Tong et al., 2005).  
 15 
 
The mechanism of Lcn2 induced apoptosis remains unclear. In 2005, Devireddy et al. 
(Devireddy et al., 2005) proposed a hypothesis that links Lcn2 induced apoptosis and iron 
delivery. In the hypothesis, an Lcn2 cell membrane receptor mediates the intake of Lcn2. In 
the cell, there is proposed to exist a siderophore-like molecule that binds iron with high 
affinity. Once inside the cell, Lcn2 binds the siderophore-iron complex. The subsequent 
export of Lcn2-siderophore-iron out of the cell leads to iron depletion, which causes the cell 
to undergo apoptosis. They cloned a proposed receptor of Lcn2 (24p3R) and overexpressed it 
in Hela cells. They found the 24p3R expression promotes Lcn2 uptake by 24p3R cells. They 
also reported that both iron loaded Lcn2 (holo-Lcn2) and iron unloaded Lcn2 (apo-Lcn2) can 
be taken up by cells expressing 24p3R, but the apo-Lcn2 specially mediates intracellular iron 
depletion and apoptosis. These results support the hypothesis. However, they did not show 
the protein binding of the 24p3R and Lcn2, and the endogenous siderophore like molecule is 
not found yet (Devireddy et al., 2005). 
Recently, EX-FABP was proposed as a cell survival factor. In one paper, Ex-FABP 
expression was down-regulated by simultaneous expression of EX-FABP antisense RNA in 
chicken embryo chondrocytes. The researchers observed an increase in the number of 
apoptotic chondrocytes. The expression of antisense RNA to EX-FABP also induced 
extensive myoblast cell death (Eddi Di Marco, 2003). Another paper reported that EX-FABP 
is diffusely expressed in chicken embryos at 3.5 days of development. Direct microinjection 
of EX-FABP antibody into chicken embryos induced significant cell apoptosis in embryo 
hearts, which eventually led to embryonic death (up to 70% of embryos died). The authors 
suggested that the role of EX-FABP as a scavenger for fatty acids is the reason that it 
promotes cell survival (C. Gentili, 2005). 
1.4.5 Cancer and Other Possible Functions 
In the rat, NRL expression is associated with breast cancer induced by neu. However, 
this is not true for human beings. The relationship of Lcn2 and breast cancer is not clear. 
NGAL expression in breast cancer is heterogeneous: some patients samples have NGAL 
expression while some do not and some are ambiguous. It was once suggested as a putative 
in vivo estrogen target gene and a new therapeutic target gene for breast cancer prevention 
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and treatment as in a mouse model (Seth et al., 2002). But no other reports support this 
opinion.  
NGAL may play a role in breast cancer growth. The complex of NGAL and 
gelatinase B (MMP-9), which is found in human neutrophils, can form in vitro by mixing 
NGAL and MMP-9. It appears that, when complexed with MMP-9, NGAL can protect the 
MMP-9 from degradation and preserve the MMP-9 enzymatic activity (Yan et al., 2001). 
One group reported that NGAL overexpression stimulates MCF-7 breast cancer cells growth 
in immune-deficient mice, and a higher level of MMP-9 was detected in NGAL-
overexpressing tumors compared to the wild type tumor. The explanation is that protection of 
MMP-9 activity facilitates tumor angiogenesis and tumor growth. The NGAL/MMP-9 
complex is present in the urine of breast cancer patients, and detection of the complex may 
be used as a noninvasive method for predicting disease status of breast cancer patients 
(Fernandez et al., 2005). However, protection of MMP-9 is probably unique to NGAL, 
because NGAL is the only Lcn2 ortholog with a free Cys residue and forms a complex with 
MMP-9, while uterocalin and NRL do not form the complex with MMP-9 because they do 
not have the third free Cys residue. 
Lcn2 suppression of cancer cell invasiveness and metastasis has been reported (Hanai 
et al., 2005). The metastatic potential of the breast cancer model (4T1 cell line) was 
accelerated by the introduction of an active mouse H-Ras mutant. Overexpression of 
uterocalin converted the 4T1-Ras-transformed tumor cells to an epithelial phenotype with an 
up-regulation of E-cadherin expression. Suppression of cell invasiveness in cell culture and 
tumor growth and lung metastases in vivo was also observed (Hanai et al., 2005). Others 
reported suppression of the invasion and liver metastasis of colon cancer cells with 
expression of NGAL (Lee et al., 2006). NGAL expression was also found in other tumor cell 
lines and tumor tissues, such as in pancreatic tumors and pancreatic cell lines. NGAL 
expression in colorectal and hepatic tumor tissues is significantly higher than in normal 
tissues. But the function of NGAL expression in these tumor tissues is not clear (Furutani et 
al., 1998).  
There are other proposed characteristics or functions of Lcn2. For example, NGAL 
induced cell migration was reported. NGAL can stimulate mouse inner medullary collecting 
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duct (mIMCD)-3 cell migration and was required for efficient mIMCD-3 cells tubulogenesis 
in cell culture (Gwira et al., 2005). Uterocalin increased cell migration in cell culture and 
facilitated rat mucosal regeneration by promoting cell migration in vivo via subcutaneous 
administration (Playford et al., 2006). Uterocalin is associated with sperm mobility or 
activity. Addition of uterocalin enhanced sperm progressive motility but not hyper-activated 
movement. This implies that uterocalin may play a role in flagellar motility regulation (Lee 
et al., 2003). Uterocalin has the ability to inhibit the acrosome reaction in BSA stimulated 
sperm in vitro (Lee et al., 2005). Uterocalin can be phosphorylated by PKC in vitro and the 
phosphorylated form of uterocalin was detected in the mouse uterus (Lee et al., 2001).  
1.4.6 Biomarker for Diseases  
NGAL is in the secondary granules of neutrophils and is secreted during neutrophil 
degranulation. Thus, its serum concentration may reflect granulocyte activity and can be used 
as a marker for some diseases. NGAL was one of biomarkers used to evaluate granulocyte 
activation in atherosclerosis (Elneihoum et al., 1997). It was suggested as an even more 
sensitive and specific diagnostic tool than myeloperoxidase (MPO) to monitor neutrophilic 
inflammation in cystic fibrosis (Eichler et al., 1999). Both NGAL and MPO can be detected 
in lung lavage fluid and lung tissue. NGAL was suggested as a better marker to measure 
neutrophil cell activity within the airspace than MPO because its concentration is less 
variable (Schmekel et al., 2000). NGAL, mostly in the dimeric form, increased more than 4 
fold in the plasma after cardiac surgery. The release of NGAL was suggested as a result of 
inflammatory activation of neutrophils caused by the extracorporeal circulation (ECC) used 
during cardiac surgery (Jonsson et al., 1999). In ulcerative colitis, a significant increase in 
NGAL was detected in rectal dialyzates and feces but not in the serum (Nielsen et al., 1999). 
NGAL was suggested as a predictor for the long-term mortality after cerebrovascular 
ischemia, because it indicates leucocyte activation (Falke et al., 2000).  
NGAL expresses in the epidermis but solely within the hair follicles in normal adult 
skin. However, NGAL expression is strongly induced in the epidermis in skin disorders that 
are characterized by dysregulated epithelial differentiation. The confined NGAL expression 
in adult parakeratotic epidermis makes it a marker for dysregulated keratinocyte 
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differentiation in human skin (Mallbris et al., 2002). NGAL expression in Kawasaki disease 
is higher than normal for a long time after onset of the disease as a result of sustained 
neutrophil activation (Biezeveld et al., 2005).  
NGAL is suggested as a useful marker in the diagnosis of acute bacterial infections 
because the serum NGAL level increases only in acute bacterial but not in viral infection (Xu 
et al., 1995). It was also selected as a useful early marker of neonatal bacterial infection 
because NGAL is rapidly released by neonatal neutrophils upon microbial stimulation in vivo 
(Bjorkqvist et al., 2004). In the mouse and rat models, Lcn2 expression is highly increased in 
the kidney and can be easily detected in urine after ischemic renal injury. The increase of 
NGAL even precedes the increase of traditional markers such as β-2 microglobulin and N-
acetyl-beta-D-glucosaminidase (NAG). The rapid increase of NGAL after ischemia makes it 
an early urinary biomarker for ischemic renal injury (Mishra et al., 2003). 
 
1.5  Human Breast Development 
The breast is an important and complex organ for the nursing and survival of the 
newborn. There are two tissue compartments, the epithelium and the stroma, that constitute 
the mammary gland. The epithelial cells form ducts and milk-producing alveolar cells and 
the stromal cells form the mammary fat pad. Human breast development starts during 
embryonic life. Throughout early life, the breast undergoes dramatic size, shape, and 
functional changes in association with puberty, pregnancy, lactation, weaning and 
postmenopausal regression (Vorherr, 1974b). The breast remains relatively quiescent after 
birth until puberty. At puberty, the breast grows fast with lobule formation, and gains its 
mature shape after puberty. However, breast development and differentiation persist until the 
end of the first full term pregnancy. The breast attains its maximum development at the end 
of pregnancy, secretes milk during lactation and involutes after weaning. The breast regresses 
after menopause (Russo and Russo, 2004). 
1.5.1 Prenatal, Perinatal and Infant Breast Development 
The mammary gland parenchyma is derived from the ectoderm around the fifth week 
of gestation in the human. The mammary ridge, a 4 to 6 layer epithelial band in the thoracic 
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area forms during the sixth and seventh weeks of gestation, becoming the mammary gland. 
Because of the variation in the nomenclature and the difficulty in establishing the exact time 
of conception, it is difficult for authors to agree on the exact time of appearance of each 
structure. The Russos consider that correlation of the phases of mammary gland development 
with embryonic or fetal length is a more accurate method for describing prenatal breast 
development. They constructed a table in which they divided the mammary gland 
development during gestation into 10 different stages [Table 1] (Russo and Russo, 2004; 
Vorherr, 1974b). 
 
Stage Mammary gland development Embryo-fetal stage 
1 Ridge stage Less than 5mm embryo 
2 Milk hill stage More than 5.5-mm 
embryo 
3 Mammary disc stage Around 10–11mm embryo
4 Lobule type stage 11.0–25.0-mm embryo 
5 Cone stage 25–30-mm embryo 
6 Budding stag 30–68-mm embryo 
7 Indentation stage 68-mm to 10 cm 
8 Branching stage 10 cm fetus 
9 Canalization stage 20 and 32 weeks of 
gestation 
10 End-vesicle stage, in which the end 
vesicles are composed of a monolayer of 
epithelium and contain colostrums 
Newborn 
 
Table 1. Stages of prenatal development of the human breast. (Reprinted from (Goetz et al., 
2002), Copyright (2004), with permission from Elsevier) 
 
At birth, the mammary discs may be observed in neonates of both girls and boys 
because of stimulation of fetal mammary gland tissues by the maternal luteal and placental 
sex steroids (Vorherr, 1974b). The newborn breast contains very primitive structures that are 
composed of short ductules. The ductules are lined by one to two epithelial cell layers and 
one myoepithelial cell layer. The morphological structures of the breasts in boys and girls are 
similar from birth to puberty. However, the variation in the degree of glandular development 
(branching and acinar formation) and the functional differentiation of the cells lining the 
ducts and acini is huge between individuals, even between breasts of the same individual. 
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Beatrice et al. (Beatrice and Barry, 2000) proposed a system to represent the prepubertal 
breast. In their system, three morphological types describe the degree of glandular 
development and branching complexity and five functional stages describe the secretory 
activity and glandular involution. Various combinations of morphological types and 
functional stages were observed and used to describe the breast. However, there is no clear 
correlation between the morphological types and the functional stages (Beatrice and Barry, 
2000; Russo and Russo, 2004). 
The cells forming the epithelial compartment of the mammary gland were proposed 
to be derived from mammary stem cells (MSCs). MSCs have the capacity to renew 
themselves and give rise to committed epithelial precursor cells (EPCs). The progeny of 
EPCs are destined to one of two fates. One is the ductal fate, in which they become ductal 
precursor cells (DPs) that form ducts. The other is the alveolar fate, in which they become 
alveolar precursor cells (APs) that give rise to differentiated milk-producing cells 
(Hennighausen and Robinson, 2005). That a small section of transplanted mammary gland 
duct can generate an entire ductal tree in a cleared fat pad is evidence of the presence of the 
stem cells (Kordon and Smith, 1998). Most epithelial cells in postnatal mammary tissue 
express estrogen and progesterone receptors, and the infant breast is able to respond to 
maternal hormones. This is the reason for the generalized secretory activity of the newborn 
gland (Keeling et al., 2000). However, the differentiated infant breast undergoes involution 
once the influence of the maternal hormones has faded. The infant breast contains only small 
ductal structures in a fibroblastic stroma and remains in this state until puberty (Beatrice and 
Barry, 2000; Jean W. Keeling, 2000; Russo and Russo, 2004).  
1.5.2 Pubertal Development of the Human Breast 
The breast initiates its development at puberty. An early sign of breast development is 
increased tissue succulence and visible elevation of areola mammae and the nipple. The first 
recognizable enlargement of the breast disc usually occurs at 10-years of age. Changes of the 
breast in form and size during this period may last for 2-3 years. This adolescent period 
terminates with sexual maturity (Jose Russo, 2000; Vorherr, 1974b). 
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The gross change in the breast at puberty is caused by both epithelial and stromal 
growth. The amount of fibrous and fatty tissue increases in the stroma and the stromal tissue 
functions as a matrix for the growth of the ducts (Beatrice and Barry, 2000). The growth and 
division of the primary ducts, which are a combination of dichotomous branching ducts 
(dividing into two parts) and sympodial branching ducts (forming an apparent main axis from 
successive secondary axes), contribute to the increase of the parenchyma of the breast (Russo, 
1996; Russo J, 1982). 
Ductal elongation and formation of lobular structures in the female breast during 
puberty is under the influence of hormones (Beatrice and Barry, 2000). Ovarian hormones, 
especially estrogens and progesterone, are important to the growth of mammary ducts. But in 
early puberty there is only a small amount of progesterone available because ovulation of the 
primordial follicles is absent. Hence, the major inductive factor of breast development is 
estrogens in this period. Later during puberty, with ovulation of the ovary, progesterone is 
available, and breast development occurs under the influence of both estrogens and 
progesterone (Vorherr, 1974b).  
Growth hormone (GH) also plays a role in breast development. GH directly 
stimulates ductal tree elongation and branching during puberty, although the exact 
mechanism of regulation is unclear. In hypophysectomized–ovariectomized rats, ductal 
growth is under the direct influence of GH. This effect of GH on breast development might 
work through its local mediator, insulin-like growth factor I (Jose Russo, 2000).  
The main morphological structure of the breast during puberty is a cluster of 
approximately 11 alveolar buds around a terminal duct. In the morphological classification of 
Dr. Russo, the structure is named as type 1 (Lob 1) or virginal lobule. Alveolar buds 
originate from the club-shaped terminal end buds (TEB), which result from dichotomous and 
sympodial division of the primary ducts. Each TEB divides into two alveolar buds. Alveolar 
buds become smaller with further branching and form ductules. The lining of the TEB and 
ductules are two-layered epithelia [Fig 4, lobular structure] (Jose Russo, 2000; Russo and 
Russo, 2004). 
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1.5.3 The Adult Human Breast 
The shape of the breast is determined mainly by connective tissue growth and fat 
deposition under the influence of hormones. The breast usually obtains its definite adult 
shape after the age of 15 (Vorherr, 1974b). Development of the epithelial tissue persists after 
the breast gains its mature shape. Besides the type 1 lobule, two other identifiable types of 
lobules can be found in the normal breast tissue of adult women. They are designated as type 
2 (Lob 2) and type 3 (Lob 3) lobule. Lob 2 and Lob 3 are the result of further differentiation 
of Lob 1. The alveolar buds of Lob 1 sprout new ductules to form Lob 2 and Lob 3 with the 
result that there are more ductules in Lob 2 and Lob 3 than in Lob 1. There are approximately 
47 and 80 ductules in Lob 2 and 3 respectively, but there are only 11 ductules in Lob 1. 
During the transition from Lob 1 to Lob 2, or Lob 2 to Lob 3, the lobule size enlarges. 
 
Fig. 4 
Figure 4. Diagrammatic representation of the lobular 
structures of the human breast. (Reprinted from (Goetz et al., 
2002), Copyright (2004), with permission from Elsevier) 
 23 
 
However, the size of the individual ductule structure, which forms the lobule, is reduced 
(Jose Russo, 2000; Russo and Russo, 2004).  
Although all three types of lobule can be observed in the nulliparous breast, their 
distributions differ. Lob 1 is the predominate structure in the nulliparous breast and remains 
constant with breast development. Lob 2 and Lob 3 can be seen in the nulliparous breast, but 
in much fewer numbers than Lob 1. However, huge variations exist in the breast structure 
among normal nulliparous women and even between the breasts of the same woman, which 
makes it very difficult to define states of the breast solely by the distribution of lobules 
(Beatrice and Barry, 2000; Jose Russo, 2000; Russo and Russo, 2004). Although the stromal 
tissue may accomplish its differentiation as early as the age of 14-15 years, the epithelial 
tissue maintains its developmental state for many years under the influence of cyclic ovarian 
sex hormones (Vorherr, 1974b). 
1.5.4 Pregnancy and Lactating Human Breast 
During pregnancy, the breast changes in appearance and structure, such as the 
intensification of the pigmentation of the areola and nipple and the enlargement of the areola 
mammae. The breast, especially the peripheral mammary areas, also enlarges. It is believed 
that the enlargement of breast during pregnancy is caused mostly by extensive ductular-
lobular-alveolar growth. The growth is induced by multiple luteal and placental hormones, 
but the estrogens and progesterone are the most important hormones. During pregnancy, the 
fat and connective tissue decrease in proportion to the breast as a result of dilation of the 
alveoli, colostrum accumulation and vascularization enhancement (Vorherr, 1974b).   
Two morphological phases are observed in pregnant breast development. The first 
phase starts as early as 3 to 4 weeks of gestation and is characterized by ductal lengthening 
and profuse branching. As a result of the rapid formation of ductules, more Lob 2 and Lob 3 
are formed. Besides the hypertrophy of preexisting structures, new lobular formation also 
exists in the breast. The second phase starts at the end of the third month when alveoli begin 
to show secretory function. At this phase, a new type of lobule, the Lobule type 4 (Lob 4) 
presents in the breast. Lob 4, found only in parous women and not in nulliparous women, is a 
fully differentiated structure and has characteristic single cell layered secretory acini. The 
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epithelial cells of the acini increase greatly in number due to active cell division and they also 
increase in size mainly by cytoplasmic enlargement (Russo et al., 2005; Russo and Russo, 
2004; Vorherr, 1974b). 
Development of the ductal tree is accomplished by the end of the first half of 
pregnancy and the breast gains its secretory function. The second half of gestation is 
characterized by continuation and accentuation of the secretory activity with only minor 
additional branching. The formation of differentiated secreting acini becomes more evident 
during this period. At this time, the epithelial cells are highly differentiated and only show 
minimal proliferative activity. Colostrum, secretory material composed of desquamated 
glandular and phagocytic cells, begins to fill the already formed luminae. The secretion of 
colostrum augments as the pregnancy advances. The breast becomes firm and full and ready 
for lactation at term (Russo and Russo, 2004; Vorherr, 1974b). 
The morphological changes of the mammary gland during lactation are minor with 
the observation of enlargement of lobules and dilation of acini. However, the alveolar cells, 
under the influence of a neuroendocrine control, achieve a conversion from the presecretory 
stage into an active milk protein synthesizing and releasing stage. Lactogenesis is the 
synthesis and release of milk into the mammary acini and ductal system. It is induced mainly 
by the combination of a high level of prolactin and a rapid withdrawel of estrogens, 
progesterones and placental lactogen after parturition. Colostrum, which is rich in minerals 
and immune factors and low in lactos, is secreted in the first 3-5 days. Secretion of mature 
milk, which has a higher concentration of lactose and a lower concentration of sodium and 
chloride, starts to be evident in the mother by day 10 of lactation. The initiation of 
lactogenesis does not require suckling of the infant, but it is important to maintain lactation 
because the removal of milk from the breast is critical for the alveolar cells to maintain the 
ability of milk secretion. Milk can be stored for up to 48 hours in the acini and ductal system 
before the reduction of milk secretion begins. If the milk is removed regularly from the 
mammary gland, lactation of women can be maintained for up to 4 years (Picciano, 2003; 
Russo et al., 2005; Vorherr, 1974b). 
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1.5.5 Postlactational Involution 
When milk removal is discontinued, prolactin secretion decreases and mammary 
gland involution ensues. However, postlactational involution is mostly because of the 
inhibitory effect of the milk stored in the mammary gland ductal system. Milk storage causes 
alveolar distention and tissue hypoxia and eventually inhibits further milk synthesis. Two 
complementary mechanisms are responsible for postlactational mammary gland tissue 
regression. One is cell autolysis because of reduced alveolar oxygen and nutrient supply. The 
other factor is the subsequent round of phagocytic cell infiltration and phagocytosis of the 
degenerated and necrotic alveolar material. During this process, the cellular borders 
disappear, the acinar structures collapse, and the tubules become narrow. But the ducts show 
little change in this process. All these changes lead to the reduction of the lobular-glandular 
element. New formation of connective tissue follows parenchymal reduction. The 
involutional process may take 3 months in the human and eventually the two layered 
epithelia of the resting mammary gland are reformed. However, the breast structure after 
involution is not the same as the nulliparous breast. The involuted breast retains more 
glandular tissue (mainly Lob3) compared to nulliparous breast (mainly Lob1). The structural 
changes of the breast will repeat in successive rounds of pregnancy and involution (Beatrice 
and Barry, 2000; Russo et al., 2001; Russo et al., 2005; Russo and Russo, 2004; Vorherr, 
1974a). 
1.5.6 Menopausal Involution 
Ovarian hormones have an important effect on development of the breast. However, 
the production of ovarian steroids in women decreases during the perimenopause period to 
almost complete cessation after menopause, which is characterized by amenorrhea. With the 
decrease and cessation of production of ovarian steroids, the breast undergoes involution, 
both in parous and nulliparous breasts. Menopausal involution is different from 
postlactational involution because lobules and ducts are both reduced in number during 
menopausal involution whereas ducts show little change during postlactational involution. 
Menopausal regression of the mammary gland starts from the glandular epithelium and parts 
of the connective tissue disappear along with it. As a result of regression, the numbers of 
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Lob2 and Lob3 are reduced and the number of Lob1 is augmented. At the end of the fifth 
decade of life, the histological appearance of the breast of nulliparous and parous women is 
almost identical and both contain predominantly Lob1 structures. Because premenopausal 
parous women have more Lob2 and Lob3 in their breasts than in breasts of nulliparous 
women, their regression is different in a qualitative aspect although the results of involution 
are the same. During menopausal involution, fat is deposited in the breast and replaces the 
glandular epithelium and the connective tissue. Only a few acini and ducts remain after 
involution (Beatrice and Barry, 2000; Russo et al., 1992; Russo and Russo, 2004; Vorherr, 
1974a).  
1.5.7 Pregnancy and Breast Cancer 
Breast cancer is the major cancer afflicting women of western world countries. It is 
estimated that more than ten percent of women in the U.S. have a lifetime risk of developing 
breast cancer. After lung and bronchial cancer, breast cancer is the third leading cause of 
cancer deaths in the U.S. (Jemal et al., 2003). 
Reproductive history, such as early menarche, menopause and parity, is a consistent 
risk factor among many others for breast cancer. However, one of the strongest protective 
factors for breast cancer is also related to reproductive history: a full term pregnancy early in 
life (early 20s) gives a 50% reduction of lifetime risk of breast cancer when compared with 
the risk in nulliparous women. Although additional pregnancies further increase the 
protective effect, the greatest protection is from the first early full term pregnancy. The 
protective effect of a full term pregnancy early in life has been demonstrated in many 
epidemiological studies and is considered by some researchers as a practical and affordable 
way for prevention of breast cancer in humans (Bernstein, 2002; Lambe et al., 1996; 
MacMahon et al., 1970). 
The protective effect of an early full-term pregnancy against breast cancer is also 
observed in experimental rodent models. Rats and mice have long served as animal models 
for chemically induced breast cancer research. Rats and mice that have undergone a full term 
pregnancy also gain protection against chemically induced mammary carcinogenesis when 
compared with nulliparous animals (Russo and Russo, 1996; Sinha et al., 1988; Welsch, 
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1985). Although most published papers report the use of rats in these experiments, the fully 
developed technology for preparing transgenic and knockout mice will provide an advantage 
to using mice in breast cancer studies. 
Ovarian steroid hormonal changes during pregnancy have been suggested as an 
explanation for the protective effect of pregnancy against breast cancer. The mammary gland 
is expected to have high levels of estrogens and progesterone during pregnancy. In the 
experimental rodent models, a short-term treatment with estrogen and progesterone to mimic 
the effect of pregnancy, prior to or after treatment with the chemical mammary carcinogen, 
also induced protection against breast cancer both in mice and rats (Guzman et al., 1999; 
Medina and Kittrell, 2003; Medina and Smith, 1999; Sivaraman et al., 1998; Yang et al., 
1999). However, despite the well-documented data, the mechanisms of pregnancy/hormone-
induced protection against breast cancer still remain unclear. Breast cancer incidence reaches 
its peak after menopause when the morphology of the breast is the virtually the same in 
parous and nulliparous women with  Lob1 structure as the main epithelial structure, (Jemal et 
al., 2003). However, the nulliparous women are at higher risk of developing breast cancer 
while parous women are protected (Russo and Russo, 2004). Hypotheses to explain this 
effect include 1) pregnancy or hormone treatment caused differentiation of the mammary 
gland. Differentiation may remove a population of cancer susceptible cells (in the terminal 
end buds) and hence protect the mammary gland from cancer (Russo and Russo, 1997), 2) 
susceptibility of the mammary gland to cancer is modulated by the hormonal milieu, which 
results in persistent biochemical alterations in the mammary epithelia (Swanson et al., 1995), 
3) the developmental fate of a subset of mammary epithelial cells is affected by the hormonal 
milieu of pregnancy and this increases protection against breast cancer (Medina and Kittrell, 
2003; Swanson et al., 1995). 
1.5.8 Macrophages and Mammary Gland Development 
Macrophages are differentiated from blood monocytes, are recruited into tissues and 
can be found in every tissue (Gouon-Evans et al., 2000). They are given special names in 
some tissues such as osteoclasts (bone), microglia (brain), Kupffer cells (liver) and mesangial 
cells (kidney). Macrophages play an important role in host defense against pathogens and are 
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thought to participate in tissue remodeling during development and tissue homeostasis 
(Gouon-Evans et al., 2000). 
Macrophages are also found in the mammary gland. They are involved in regulating 
ductal morphogenesis, which is an important aspect of postnatal mammary gland 
development. Macrophages are found mainly around the neck of the terminal end buds and 
not associated with the ductal structures distal to the terminal end buds during pubertal 
mammary gland development in the mouse (Gouon-Evans et al., 2000; Ingman et al., 2006). 
Depletion of the macrophage population from the mammary glands by whole body 
(-irradiation or by knockout of Colony Stimulating Factor-1 (CSF1), which is required to 
recruit macrophages into mammary glands, results in delayed formation, reduced numbers 
and a shorter and rounder form of the terminal end buds compared to those in the control 
glands (Gouon-Evans et al., 2000; Ingman et al., 2006). The defects of the terminal end buds 
have been shown to be directly due to macrophage depletion because restoration of the 
macrophage population in the mammary gland rescues these defects (Gouon-Evans et al., 
2000; Ingman et al., 2006). Thus, macrophages are required for ductal morphogenesis in 
postnatal mammary gland development. 
Macrophages are also found dispersed throughout the adipose tissue of the mammary 
fat pad (Schwertfeger et al., 2006). The exact function of macrophages in the fat pad is not 
clear, but it is most likely that they are involved in phagocytosing dying adipocytes (Cinti et 
al., 2005). Phagocytosis performed by macrophages may also be important for mammary 
gland remodeling during involution because many cells undergo apoptosis and need to be 
removed (Li et al., 1997; Lund et al., 1996). Macrophages in the mammary gland help to 
clear residual milk and apoptotic cells, although the mammary gland epithelial cells are also 
capable of phagocytosis (Helminen and Ericsson, 1968; Helminen and Ericsson, 1971; 
Walker et al., 1989). Earlier studies showed no increase in the population size of 
macrophages in the mammary gland during involution (Mayberry, 1964; Richards and 
Benson, 1971). But, recent data from microarray and histological studies of involuting 
mammary glands provided evidence for there being more macrophages in the mammary 
gland during involution (Clarkson et al., 2004; Stein et al., 2004). The increase in 
macrophages in the mammary gland during involution is believed to be due to monocyte 
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infiltration and subsequent differentiation into macrophages (Stein et al., 2004). This increase 
of macrophages is proposed to help remove apoptotic cells (Hanayama and Nagata, 2005; 
Monks et al., 2002). But the fate of the macrophages that infiltrate into the mammary gland 
during involution is not clear. D’Cruz et al reported that the expression of two macrophage 
specifically expressed genes, macrophage expressed gene 1 and macrophage metalloelastase, 
increases in fully involuted parous mouse mammary glands compared to virgin mammary 
glands in their microarray study (D'Cruz et al., 2002). This study supports the hypothesis that 
some macrophages may stay in the mammary gland after completion of involution, although 
there is no immunohistological study to confirm this finding.   
1.5.9 Macrophage and Cancer 
That surveillance provided by the immune system, including macrophages, might 
suppress the initiation of cancer was proposed a long time ago (Burnet, 1957). In a recent 
model, three stages in cancer are proposed.  These are immunoediting (destruction of tumor 
cells by the immune system), equilibrium (tumor cells gain the ability to survive an immune 
attack), escape (tumor cells grow and expand in the immunocompetent host) (Dunn et al., 
2002). According to this model, macrophages, together with other immune cells such as NK 
cells, are recruited to the tumor site and destroy tumor cells during the elimination stage 
(Dunn et al., 2002).  
Tumor-associated macrophages (TAMs) promote growth and spreading of tumor 
cells (Elgert et al., 1998; Lin et al., 2002). This presents a paradox in which macrophages can 
both destroy tumor cells and promote tumor development.  The explanation of this apparently 
paradoxical role of macrophages on tumor cells is the functional plasticity of macrophages 
(Sica et al., 2008).  Two subsets of macrophages have been defined based on the secretion of 
either IL-12 (M1) or IL-10 (M2) in response to inflammatory stimuli (Trinchieri, 2003).  M1 
macrophages are considered to function in killing microorganisms and tumor cells, while M2 
macrophages are able to promote angiogenesis, tissue remodeling and repair (Mantovani et 
al., 2004). Macrophages can be phenotypically polarized by the microenvironment to have 
either M1 or M2 function. For example, the classic activation signals such as LPS and IFN-( 
induce the differentiation of macrophages into M1 phenotype’ while signals such as IL-10, 
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IL-3, IL-4 or glucocorticoid hormones induce the differentiation of macrophages into M2 
phenotype (Gordon and Taylor, 2005; Mantovani et al., 2002). The phenotype of TAMs is 
similar to that of M2 macrophages (Sica and Bronte, 2007). Thus, an explanation for the 
paradoxical role of macrophages on tumor cells is the following: M1 phenotype macrophages 
can cause death of tumor cells so they function in the elimination stage of the three-stage 
model and help to decrease cancer incidence. However, tumor cells have the ability to form a 
microenvironment that promotes macrophages to convert to the M2 phenotype that can then 
promote the growth of tumor cells during the escape stage (Sica and Bronte, 2007; Sica et al., 
2008). 
 
1.6  Mycoplasma  
Mycoplasmas are a heterogeneous group of prokaryotes. They are the smallest 
organisms, in both cellular dimensions and genome size, which are capable of self-replicating 
and cell-free existence (Wilson and Collier, 1976). The first mycoplasma was described as 
the bovine pleuropneumonia agent by Nocard and Roux in 1898, and the name 
pleuropneumonia-like organisms (PPLO) was used for a period of time (Waites and 
Talkington, 2004). Mycoplasmas are distinguished from other bacteria by their minute size (1 
to 2 µm long and 0.1 to 0.2 µm wide), total lack of a cell wall, cholesterol requirement for 
survival, small genome size (580kb to 1350kb) and low GC content (23-40%) (Razin et al., 
1998).  
Mycoplasmas are widespread in the animal kingdom. More than 100 species of 
mycoplasma have been identified. The primary habitats of human and animal mycoplasmas 
are the mucous surfaces of the respiratory and urogenital tracts, mammary glands, joints and 
the eyes (Razin et al., 1998). Mycoplasmas live an obligate parasitic mode of life and are 
usually host-specific. However, some mycoplasmas have a broader host range. For example, 
Mycoplasma bovis, which can cause mastitis in cattle, is also found in human (Pitcher and 
Nicholas, 2005).  
 Mycoplasma infection is a common problem in cell cultures. It was estimated that 5-
87% of cell lines are contaminated with mycoplasmas depending on the sensitivity of the 
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method used to detect the infection (Hay et al., 1989; Rawadi and Dussurget, 1995). The 
main source of mycoplasma contamination of clean cell cultures is believed to be previously 
infected cultures. Laboratory personnel and commercial sera used in culture media are less 
common sources in mycoplasma contamination (Hay et al., 1989). Among the more than 100 
mycoplasma species, 5 species account for more than 95% of cell contaminations. They are 
Mycoplasma arginini, Acholeplasma laidlawii, Mycoplasma orale, Mycoplasma fermentans 
and Mycoplasma hyorhinis (Bolske, 1988; McGarrity et al., 1986; Ossewaarde et al., 1996; 
Rawadi and Dussurget, 1995). 
Contamination of cell cultures by mycoplasmas is more difficult to notice than 
contamination by bacteria and fungi because they can not be visualized under an inverted 
microscope and the medium is not turbid even though the concentration of mycoplasmas in 
the medium can be as high as 107-108 colony forming units (cfu) per milliliter. Mycoplasmas 
also usually exert no cytopathogenic effects on the host cells. In addition, mycoplasmas are 
resistant to the antibiotics commonly used in long-term cell cultures (such as penicillin) (Hay 
et al., 1989; Rawadi and Dussurget, 1995; Uphoff et al., 1992). All these reasons make 
periodic screening for mycoplasmas an important procedure to control contamination in cell 
cultures.  
Many methods are used to detect mycoplasma in cell cultures such as microbial culture, 
DNA fluorochrome staining, immunofluorescence, biomedical assay and others. But 
currently, PCR is the preferred method to detect mycoplasma specific genes for screening 
because it is easy, fast and sensitive (Gopalkrishna et al., 2007; Kong et al., 2007; Rawadi 
and Dussurget, 1995; Uphoff et al., 1992). 
Although mycoplasmas in contaminated cell cultures usually exert no obvious damage 
to the cells, they are capable of affecting the properties of cultured cells such as their growth, 
morphology and physiology (Doersen and Stanbridge, 1981; Hay et al., 1989; Rawadi and 
Dussurget, 1995). For example, HeLa cells were more sensitive to the cytotoxic effect of 
chloramphenicol (CAP) after being infected with a CAP-resistant strain of M. hyorhinis 
(Doersen and Stanbridge, 1981). The growth of normal human embryonic lung fibroblast 
(HAIN-55) cells was inhibited when they were inoculated with large amount of Mycoplasma 
hominis (more than 107 cfu/ml) (Sasaki et al., 1981). Arginine deiminase，an enzyme 
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derived from Mycoplasma arginini, strongly inhibited the growth of human T cells and T 
lymphoblastoid cell lines (Komada et al., 1997). Potential malignant transformation is also an 
issue in persistent mycoplasma infected cell cultures. Infection of C3H mouse embryonic 
cells with M. fermentans or M. penetrans, two mycoplasmas found in unusually high 
frequencies among patients with AIDS, caused progressive malignant transformation of C3H 
cells. The transformation was reversible within 6 passages (1 week per passage) of infection. 
However, the transformation became permanent after 11 passages of infection. The 
malignant transformation was not caused by integration of mycoplasmal gene(s) into the 
mammalian cell genome, because no mycoplasmal gene was found in the transformed cells 
(Tsai et al., 1995; Zhang et al., 1998). 
Most mycoplasmas live as commensals. However, infections by pathogenic 
mycoplasmas can induce host inflammation (Kennedy and Ball, 1987; Lindsey and Cassell, 
1973; Peltier et al., 2003; Rollins et al., 1986). Mycoplasma infections are usually chronic 
and the damage from mycoplasma infections is more likely due to the host immune and 
inflammatory responses than of the direct toxic effect of mycoplasma (Avron and Gallily, 
1995; Razin et al., 1998). It has been shown that murine macrophages and human monocytes 
produce proinflammatory cytokines and chemokines, including interleukin-1 (IL-1), IL-6, 
tumor necrosis factor α (TNF-α), and prostaglandins as well as nitric oxide (NO) after being 
stimulated by mycoplasmas or extracts of mycoplasma membranes (Avron and Gallily, 1995; 
Gallily et al., 1992; Muhlradt and Schade, 1991; Sher et al., 1990).  
The most relevant mycoplasmal components to activate the early host inflammation 
reaction are mycoplasmal lipoproteins and lipopeptides (Luhrmann et al., 2002). In 1991, a 
high-molecular-weight material (MDHM), which is a mixture of lipoproteins, was extracted 
from Mycoplasma fermentans (M. fermentans). MDHM can induce TNF-α, IL-1 and IL-6 
production in cultures of both murine macrophages and human monocytes (Muhlradt and 
Schade, 1991). Later, the key molecule was identified as macrophage-activating lipopeptide-
2 (MALP-2), a truncated lipopeptide representing the N-terminus of MALP-404 lipoprotein 
(Muhlradt and Frisch, 1994; Muhlradt et al., 1997). Its primary structure was determined as 
(S-[2,3-bisacryl(C16:0/C18:0;C18:1)-oxypropyl]cystine-GNNDESNISFKEK (Muhlradt et 
al., 1997). MALP-2 exhibits very high macrophage stimulating activity (MSA), with a 
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reported half maximal activity at a concentration of 10-11M. That the lipid moiety is very 
important to the MSA of MALP-2 was demonstrated because nonlipidated MALP-2 was 
unable to activate macrophages (Muhlradt et al., 1997). MALP-2 is used as a representative 
molecule by many researchers for studies of mycoplasmal lipoproteins and lipopeptides. 
The effects of MALP-2 on host or cultured macrophages are similar to that of bacterial 
endotoxin lipopolysaccharide (LPS). Both MALP-2 and LPS are macrophage activators and 
have the ability to induce proinflammatory cytokines and chemokines such as IL-6 and 
TNF-" (Deiters et al., 2003; Galanos et al., 2000; Yamamoto et al., 2004). Both MALP-2 and 
LPS signal through the receptor family of Toll-like receptors (TLRs). The difference is that 
LPS acts through TLR4, while MALP-2 utilizes TLR2/6 (Kraatz et al., 1999; Morr et al., 
2002; Poltorak et al., 1998; Takeuchi et al., 2001). Whereas LPS can activate expression of 
genes through pathways other than the myeloid differentiation factor 88 (MyD88), no 
MyD88-independent pathway for MALP-2 has been reported (Kawai et al., 2001).  
The potential use of MALP-2 for the benefit of human health was reported when 
MALP-2 was proposed to be used to protect patients from gram-negative septic shock, based 
on the observation that it induces LPS cross tolerance in mice and has less systemic toxicity 
as well as pyrogenicity (Deiters et al., 2003). MALP-2 is also used as a potent mucosal 
adjuvant (Rharbaoui et al., 2002). 
 
1.7  Inflammation 
Inflammation is the response of host tissues to challenges by microbial infections or 
tissue injury. It is a coordinated process that involves the release of exogenous and 
endogenous chemical mediators, recruitment of leucocytes, and damage and destruction of 
the host tissues. In extremely serious cases, multiple organ failure or even death can occur 
(Barton, 2008; Nathan, 2002; Serhan et al., 2008). Knowledge about inflammation dates back 
to ancient time, in part because it is such a common problem. Celsus documented the tissue 
response to injury as early as in the 1st century AD (Libby, 2007). The well-established signs 
of inflammation are: rubor (redness, caused by hyperemia), tumor (swelling, due to increased 
permeability and leakage of the microvasculature), calor (heat, due to increased blood flow 
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and the metabolic activity of the inflammatory mediators), dolor (pain, in part due to changes 
in the perivasculature and associated nerve endings), and functio laesa (dysfunction of the 
involved organs) (Libby, 2007; Serhan et al., 2008).  
The first step of the inflammatory response to infection is recognition of the infection 
by the immune system. The innate immune system responds to microbial invasion rapidly by 
way of its receptors (Libby, 2007; Medzhitov, 2007). The innate immune response receptors 
target highly conserved features of microbes that are foreign to mammals, called pathogen-
associated molecular patterns (PAMPs) (Akira et al., 2001; Medzhitov, 2001). Different from 
the adaptive immune response receptors, innate immune response receptors lack specificity. 
Instead they are able to detect a broad range of microbial diversity (Libby, 2007). This 
strategy is called “pattern recognition” and the receptors are termed “pattern-recognition 
receptors” (PRRs). An example of a PAMP-PRR pair is LPS from gram-negative bacteria 
and the receptor TLR4 (Barton, 2008). In certain cases, sterile inflammation can happen 
when cell death occurs without infection, such as occurs as a result of blunt trauma or 
ischemia-reperfusion (Barton, 2008). Endogenous ligands released by dead cells (such as 
heat shock proteins) and innate receptors (such as TLR) are suggested to trigger sterile 
inflammation (Jiang et al., 2005; Mollen et al., 2006). 
The toll receptor was first identified in Droshophila, and was shown to be important for 
flies to defend against fungal infection (Hashimoto et al., 1988; Lemaitre et al., 1996). Later, 
similar proteins were found in mammalian cells and called Toll-like receptors (TLRs), which 
are closely related to type I transmembrane proteins functioning as the major PRRs (Takeda 
and Akira, 2005). TLRs are members of the Toll/IL-1 receptor (TIR) family. All TLRs 
contain a cytoplasmic TIR domain that can mediate the formation of homo- and hetero-
dimers (Akira et al., 2001). Activation of the TLRs is mainly through the IκB kinase (IKK), 
MAPK and PI3K/Akt pathways (Krishnan et al., 2007). It was also reported that transcription 
factors NFκB and IFN-regulatory factor (IRF) are activated by the TLRs to regulate the 
expression of target genes including a large number of cytokine genes (Barton, 2008; 
Krishnan et al., 2007). Although the TLRs utilize similar signaling pathways, the 
extracellular structures of TLRs are diverse, which enables individual TLRs to recognize 
distinct conserved microbial targets (Misch and Hawn, 2008). The well characterized 
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receptor-ligand pairs are TLR1/TLR2/TLR6 and lipoproteins, TLR3 and double-stranded 
RNA, TLR4 and LPS, TLR5 and flagellin, TLR7/TLR8 and single-stranded RNA, and TLR9 
and CpG motifs in DNA (Kawai and Akira, 2007; Krishnan et al., 2007).  
The most influential cells in resolving infections are tissue-resident macrophages and 
dendritic cells (DCs) that act by signaling through the PRRs on their surface (Mellman and 
Steinman, 2001). Activation of macrophages and DCs results in the release of 
proinflammatory cytokines and mediators that profoundly change the local environment of 
the surrounding tissue and vasculature (Nathan, 2002). 
The second step of inflammation is the recruitment of inflammatory cells to the site of 
infection. The local tissue is in an inflamed state because of a series of morphological and 
molecular changes of local blood vessel endothelial cells induced by proinflammatory 
cytokines (such as IL-1, IL-6 and TNF") and lipid mediators (Barton, 2008). Neutrophils are 
attracted to the infection site by following the chemotactic gradients (Smith, 1994). 
Neutrophils are the most abundant leucocytes, representing 50 to 60% of the total circulating 
leucocytes. They arrive within hours and are the first leucocytes to enter the inflamed site 
(Schleimer et al., 1989; Smith, 1994). Their primary function is phagocytosis of microbial 
organisms. Monocytes are also recruited to the inflamed site by the same inflammatory 
signals but they arrive later than neutrophils and mature into macrophages after they have 
reached the infection site (Nathan, 2006).. They are also phagocytotic and can phagocytose 
microbes (Singh et al., 2004).  
The third step in resolving infection is the elimination of microbes by the leucocytes, 
especially the neutrophils and macrophages, that were recruited to the infection site,. 
Neutrophils fight microbes with their hydrolytic enzymes and antimicrobial polypeptides that 
are present in intracellular granules, reactive oxygen species (ROS), reactive nitrogen species 
(RNS) (Smith, 1994). After phagocytosis, neutrophils direct the proteases, ROS and RNS to 
the phagocytosed microbes to denature their proteins, disrupt lipids and damage their DNA 
(Nathan and Shiloh, 2000). Neutrophils can also release these active substrates into the 
extracellular space of the inflamed site. This helps to kill nearby microbes but can also cause 
damage to the host tissues (Nathan, 2006). Neutrophils will eventually die by apoptosis in the 
inflamed site. Their debris is then removed by macrophages (Singh et al., 2004). 
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Macrophages can also phagocytose microbes and kill them by mechanisms similar to those 
used by neutrophils (Barton, 2008). 
The last step in the progression of inflammation is resolution, which is the ideal 
outcome of acute inflammation (Serhan et al., 2008). Removal of the foreign offenders is 
critical to resolution, which is a process conducted mainly by neutrophils and macrophages 
(Barton, 2008; Nathan and Shiloh, 2000).  Resolution also requires the removal and reduction 
of leucocytes and their debris (Henson, 2005). Neutrophil debris is removed by macrophages 
and living neutrophils can return to the blood. Macrophages use the lymphatic drainage 
system to leave the inflamed site after finishing phagocytosis, although a small proportion 
may die locally by apoptosis (Serhan et al., 2007). Another important aspect for resolution is 
to turn off the proinflammatory signals by anti-inflammatory mediators so as to stop the entry 
of new leucocytes into the inflamed site (Henson, 2005). For example, lipoxins are anti-
inflammatory mediators produced from arachidonic acid by lipoxygenases (Serhan, 2005; 
Serhan and Savill, 2005). They help to reduce the influx of neutrophils and increase the 
influx of macrophages to clean the inflamed site (Serhan, 2005). Inhibition of the TLR 
signaling pathway also helps to achieve resolution. For example, A20, a ubiquitin ligase 
induced by NFκB, functions as a negative feedback regulator of TLR signaling through 
degradation of NFκB (Lawrence and Gilroy, 2007). 
Complete resolution is achieved and homeostasis is restored if all processes mentioned 
above are followed. However, acute inflammation has other fates if the injury is too 
extensive or persistent. Fibrosis, sclerosis or scaring can result from the host’s attempts to 
maintain structural integrity by using fibrotic material for replacement (Henson, 2005). 
Chronic inflammation can be another fate of acute inflammation if it persists for a prolonged 
time  (Lawrence and Gilroy, 2007).  
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2.1  ABSTRACT 
Pregnancy is a well established protective factor against breast cancer. One 
explanation for this protection is the increased differentiation status of the parous epithelium.  
However, this does not explain the association of parity with increased aggressiveness of 
breast cancers, particularly cancers that occur soon after pregnancy.  Because tumor 
aggressiveness can be influenced by the cell population that surrounds the mammary 
epithelium, we examined the potential role of the immune system in establishing a long-term 
difference between the mammary glands of parous and virgin animals.  Specific mRNA 
levels, enzyme activities and antigen expressing cells were quantified in parous and virgin 
mammary glands from Spraque-Dawley rats in diestrous.  Our results support the hypothesis 
that macrophages, but not neutrophils or B-cells, are specifically increased in fully involuted 
glands compared with age-matched virgin mammary glands.  Our finding of an increased 
macrophage population in the parous breast could explain the dichotomy of reported 
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association of parity with decreased breast cancer incidence and increased cancer 
aggressiveness, because of the dual role played by macrophages in opposing and supporting 
tumor progression.   
 
 
2.2  INTRODUCTION 
It is well established that parity conveys protection against cancers of the breast and 
other reproductive tissues. This correlation has been demonstrated in many studies using 
rodent models and from epidemiological analyses of human populations. Full-term 
pregnancy seems necessary for protection against breast cancer (27, 36). However, the age at 
first parity affects both the premenopausal and postmenopausal risk for breast cancer (8). A 
meta-analysis of the compiled data from 47 epidemiological studies in 30 countries, which 
included 50302 women with breast cancer and 96973 women without breast cancer showed a 
4.3% decrease in the relative risk of breast cancer for every 12 months of breastfeeding in 
addition to a 7.0% decrease in breast cancer risk for each birth (1). The study also showed 
that protection from cancer obtained by breast feeding or pregnancy was the same in 
developed and undeveloped countries. The authors concluded that almost 70% of the 
increased protection against breast cancer observed in parous females of developing 
countries can be accounted for by the larger number of births per female and the increased 
frequency of breast feeding by these latter populations (1).   
Although parity protects against the occurrence of breast cancer, it is positively 
associated with increased aggressiveness of cancer and decreased cancer survival rates (2, 9, 
20, 22, 45).  Thus, the effect of reproductive status on breast cancer is complex with full-term 
pregnancy and lactation contributing to decreased cancer incidence and increased tumor 
aggressiveness.  
A change in the differentiation state of the mammary epithelium or another cell type 
has been suggested as the reason for parity-induced protection against tumor incidence (35) 
and increased p53 expression was proposed as the mediator of this effect (29).  However, an 
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increased differentiation status of the mammary epithelium does not explain the increased 
incidence of aggressive tumors in parous compared with nulli-parous females.  
A microarray analysis of the mouse identified a small group of genes that remain 
elevated in the fully involuted mouse breast (10).  The expression levels of a number of 
epithelial growth factor genes were lower in primiparous compared with virgin animals and 
the expression of some genes associated with lymphocytes and macrophages were elevated. 
The results of this study suggested the interesting possibility that parity results in an increase 
in the immune cell population in the mammary gland and that the immune cells influence 
epithelial differentiation status and tumor aggressiveness.   
We evaluated the hypothesis that parity results in an increase in one or more 
hematopoietic cell type in the mammary gland using the diestrous rat as our model.  
Comparing breast tissue of primiparous and virgin animals we found, in the former, higher 
expression of genes that are upregulated during the innate immune response.  Our results are 
consistent with the hypothesis that parity results in a specific increase in the size of the 
mammary macrophage population.  The presence of more macrophages in the parous breast 
is consistent with more effective immune surveillance and decreased cancer incidence in 
parous compared with nulli-parous females.  
M1 macrophages, that protect against cancer, can be converted by tumor cells to M2 
macrophages that are also referred to as tumor-associated macrophages (TAMs).  Whereas 
M1 macrophages engulf tumor cells and protect against the development of cancer, M2 
macrophages are believed to promote tumor progression by secreting growth factors and 
proteases, promoting angiogenesis and suppressing adaptive immunity (40).  Cancers that do 
develop in the parous breast might be expected to be more aggressive due to the increased 
incidence of macrophages that could be converted to the M2 type and that subsequent 
influence of these macrophages on breast cancer development. Thus, our observation of a 
specific increase in the macrophage population in parous breasts leads to an overarching 
hypothesis to explain the effect of parity on breast cancer that includes the influence of the 
macrophage on epithelial differentiation, immune surveillance and tumor aggressiveness. 
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2.3  MATERIALS AND METHODS 
Materials 
Experimental Animals and Materials  
Female Sprague-Dawley rats were obtained from Harlan Company (Indianapolis, IN). 
The rats were allowed to undergo a 21 day lactation period after delivery. Rats were then 
allowed at least 28 days for complete involution of the mammary gland before being 
sacrificed. Virgin rats were sacrificed in the same week as the primiparous rats. All rats 
(primiparous and virgin) were sacrificed on the second day of diestrus, which was confirmed 
by vaginal smear.  Rats were 135 days old when sacrificed. 
All animals were housed and treated according to current NIH guidelines.  Animal 
care was provided by an animal caretaker and an attending veterinarian.  This research was 
conducted in accordance with the standards set forth in the NIH guide for the care and use of 
laboratory animals.  Animals were killed by CO2 inhalation prior to removal of tissues for the 
described studies.  Prior approval was obtained from the appropriate university Committee 
on Animal Care for all procedures performed on the animals used in these studies.  
Unless another source is identified in the text, all chemicals used were reagent grade 
or higher and purchased from Sigma (St. Louis, MO) or Fisher (Fisher Scientific Inc. Fair 
Lawn, NJ). 
RNA Extraction and Northern Blots  
Tissues were frozen immediately in liquid nitrogen upon removal from the animal 
and stored at -80 oC. Total RNA was isolated using Trizol Reagent (Invitrogen, Carlsbad, CA) 
following the manufacturer's instructions. Northern blots were performed as previously 
described with 15 µg total RNA per lane (37).  The blots were hybridized with the following 
32P-labeled probes produced by using the Megaprime DNA labeling system (Amersham 
Pharmacia Biotech, Little Chalfont, Buckinghamshire, England) with the following templates: 
Lcn2 (cDNA PCR product), SGP2 (EcoR I fragment from SGP-2 plasmid), GAPDH probe 
(XbaI-PstI fragment of a GAPDH plasmid). Between hybridizations, the membranes were 
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stripped by boiling 2 consecutive times in 0.1 X SSC with 0.1% SDS for 3 min. Data were 
obtained by exposure to a phosphorimager (Molecular Dynamics, Sunnyvale, CA).   
Real-time RT-PCR  
Reverse transcription was done as described previously (12). Briefly, 1µg total RNA 
was treated with 1 unit DNase (Invitrogen) for 15 min. After de-activation of the DNase, the 
reverse transcription was done using superscript II (Invitrogen) with 18mer oligo dT and 
dNTP. The real-time PCR was done in an Opticon (MJ research, Waltham, MA) or a Mini 
Opticon (Bio-Rad Laboratories, Hercules, CA) with FullVelocity™ QPCR Master Mix 
(Stratagene, La Jolla, CA).   Cyclophilin was used as the reference gene to normalize gene 
expression in each sample. Primers used in the experiments were: mouse Lcn2, sense: 
CAGGCCCAGGACTCAACTCAGAA, anti-sense: TCTGGACCGCATTGCCTGC; 
cyclophilin, sense: CTTTTCGCCGCTTGCTGCA, anti-sense: ACCACCCTGGCACATG-
AATCCT; rat Lcn2, sense: CAGGCCCAGGACTCAACTCAGAA, anti-sense: AGCG-
GCTTTGTCTTTCTTTCTGGA; cyclophilin: sense: CTTTTCGCCGCTTGCTGCA, anti-
sense: ACCACCCTGGCACATGAATCCT; or sense: TGTTCTTCGACATCACGGCTGAT, 
anti-sense: GGACTTGCCACCAGTGCCATTA; Igf1 sense: GGCACTCTGCTTGCTCA-
CCTT, anti-sense: CGGAAGCAACACTCATCCACA; Lbp sense: CTTGGCGTGGTCA-
CGAATGTAT, anti-sense: GGAATGCCTGGAACAGGTTCA; SPP1 sense: ATGAGT-
CCTTCACTGCCAGCAC, anti-sense: TCATCGGACTCCTGGCTCTTC; Mmp12 sense: 
GGTCAAGATGGATGAAGCGGTAT, anti-sense: TCGTAATGTCAGCCTCGCCTT; 
Mpeg1 sense: AGTGATGGATGCCAAGTGTCCTA, anti-sense: TTGGTGGCAACTTGG- 
CTCAT; TGFβ3 sense: CTGTTGCGGAGAGAGTCCAACTT, anti-sense: GGTCATCTT-
CGTTGTCCACTCCT; Emr1 sense: TTTCCTTGCCTGCTTCTTCT, anti-sense: CCTGTC-
TCCGTATTCAGCCA; CD14 sense: TACCGACCATGAAGCTTATGCT, anti-sense: 
GATTTGCTTCCGTGTCCACA; IL-6 sense: ACAGCCACTGCCTTCCCTACT, anti-sense: 
GAACTCCAGAAGACCAGAGCAGA.  
Myeloperoxidase (MPO) Assay 
The MPO assay was performed according to the method of Bradley with minor 
modifications (5). Briefly, tissues were weighed and homogenized in 1ml ice cold 0.5% 
 58 
 
HTAB, 50 mM potassium phosphate, pH 6.0. Homogenized samples were lysed by freeze-
thaw and clarified by centrifugation. 20 ul samples were assayed with an incubation time of 
10 min. The MPO activity was calculated with the formula: [(abs10min-abs0min)/10]/weight 
of tissue used/0.0113 = MPO/gram of tissue. Where 0.0113 is a constant and the weight of 
tissue used = (tissue weight/1000)*20. 
Immunohistochemistry 
A polyclonal antibody recognizing the macrophage marker CD68 was used as the 
primary antibody (Santa Cruz Biotechnology, Santa Cruz, CA). Paraffin-embedded tissue 
sections from 6 mammary glands of parous rats and 8 mammary glands of virgin rats were 
deparaffinized and rehydrated. Antigen retrieval was done by boiling the sections then 
storing them at 95ºC in 10 mM Tris-EDTA, pH 9.0. Nova Red (Vector Laboratory, 
Burlingame, CA) was used for visualizing streptavidin–biotin conjugated horseradish 
peroxidase. Sections were then counterstained with Shandon Hematoxylin (Fisher Scientific, 
Itasca, IL) to identify nuclei.  Sectioning and staining was done by the Veterinary Pathology 
Services, Iowa State University. 
Macrophages were counted from ten randomly selected fields in each section, one 
section from each tissue sample.   In each field the number of macrophages was counted.  
The counting was done blind with the identity of each sample only uncovered after the data 
had been collected.  The total number of macrophages from the ten fields of each section was 
used as the data point for that tissue sample for analysis. 
Statistics 
The standard deviation for quotient of parous and virgin group was calculated based 
on the standard deviation of each group (18). P values were calculated by t-test.  
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2.4  RESULTS 
Effects of Parity on the Expression of Immune Response genes by the 
Mammary Gland  
A previous microarray comparison of the genes differentially expressed in mammary 
glands of parous compared with virgin mice identified a set of genes associated with 
macrophages that were elevated in the parous murine breasts compared with age-matched 
virgin breasts (10).  The tissues pooled for this study were not of a defined stage in estrous 
and were done mainly with the mouse, which has not been commonly used as a model for 
parity-induced changes in breast tissue.   
We investigated the differences in gene expression between mammary glands of 
parous and virgin rats in diestrous with an emphasis on genes expressed by macrophages 
(Table 1).  Many of the genes tested in the rat tissues were the same as those identified by the 
previous microarray of mouse tissues.  However, some genes that are selectively expressed 
by macrophages were also investigated.   The results showed that the levels of several 
mRNAs that are expressed by macrophages were significantly elevated in the primiparous 
breasts.  These mRNAs included CD14 antigen (CD14), interleukin-6 (IL-6), osteopontin 
(Spp1/Eta-1), macrophage-specific matrix metalloproteinase (MMP)-12, and macrophage 
expressed gene 1 (Mpeg1) (Fig. 1).  We also found higher expression of Lbp in primiparous 
breast, but we did not find significant differences in the mRNAs levels for IGF-1,TGFβ3 and 
SGP2, all of which were previously reported to differ between the mouse parous and virgin 
tissues. Thus, the consistent finding between this study in the rat and the previous microarray 
study of the mouse mammary gland was that many macrophage markers increase with parity. 
Macrophage markers, but not Neutrophil or B-cell markere, are Elevated 
In Parous Compared With Virgin Mammary Glands. 
The population sizes of immune cells (neutrophils, macrophage, B and T cells) 
increase in the early stages of mammary gland involution (4, 6, 7, 43). Our results from gene 
expression studies that suggest an increase in the macrophage population in the parous breast  
might reflect the retention of a certain proportion of all immune cells after involution is 
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completed.  To determine which immune cell types are selectively retained in the parous 
breast after the gland had completely involuted, we tested for these cell populations using 
MPO activity (neutrophils), and the gene markers Emr1 (macrophages), B220 (B cells) and 
OX40 (T cells) (4, 14, 30). The result showed no differences in the neutrophil and B cell 
markers between primiparous and virgin mammary glands (Fig. 2). The expression of OX40 
was not detectable in any sample (data not shown).  By contrast the expression of the 
macrophage marker, Emr1, was higher in the parous compared to the virgin mammary glands 
(p<0.01).  
Macrophage are more Numerous in Parous compared with the Virgin 
Mammary Glands 
The observation of elevated levels in parous glands of mRNAs that define 
macrophages could be explained by an increase in expression of these genes per cell or by an 
increase in the number of cells in the tissue.  To determine if the macrophage population in 
primiparous glands is higher than in virgin glands we performed immunohistochemistry to 
detect and quantify macrophages.  The results demonstrated that there were more 
macrophages in the fully involuted mammary glands than in the age-matched virgin glands 
(p<0.01) (Fig. 3). 
The parity-induced changes in gene expression are specific for the 
mammary gland 
To examine the possibility that the parity-induced changes in abundance of 
macrophage markers in the mammary gland reflects a body-wide change in macrophage 
content, we examined other tissues for similar differences in level of gene expression.  For 
these studies the Lcn2 and Emr1 were chosen as the test genes and normalized to cyclophilin 
to examine specific changes in gene expression.  As seen in Fig. 4, the difference between 
parous and virgin tissues in expression of Lcn2 and Emr1 was only observed in the 
mammary gland showing that the effect of parity is specific for this gland. 
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2.5  DISCUSSION 
The participation of inflammatory cells in mammary gland involution has been 
reported in several studies in which the results of microarray analysis and histochemical 
staining indicated growth of the hematopoietic cell population, particularly neutrophils and 
macrophages, in mammary gland during involution (6, 26, 42).  However, all these studies 
were of mouse mammary glands at early stages of involution (up to 4 days of involution).  
The results of the previously cited microarray study in which mammary glands were 
examined after they were fully involuted, showed increase in markers for macrophages, B-
lymphocytes and T-lymphocytes in the involuted compared with the virgin glands (10).  
However, this study was done with a sample derived from pools of mammary glands from 
parous or virgin mice.  The inclusion in either of these pools of an infected mammary gland 
would increase the level of expression of many acute phase proteins and immune cell 
markers in the pool.  This or a difference in the species studied could be reasons why we did 
not observe increases in the levels of expression of several acute phase proteins in rat 
mammary glands that were observed in the mouse microarray study. On the other hand, our 
result is consistent with a recent microarray study of rat mammary glands in the expression 
of Lbp, Mmp12 and Spp1 (44). 
A consistent finding in our study and the microarray analysis was of significant 
increases in the levels of expression of a number of markers for macrophages.   From these 
results we reasoned that one possible explanation for the protective effect of parity against 
cancer is increased immune surveillance in the parous gland.  Therefore, we examined the 
relative levels of markers for hematopoietic cells in involuted and virgin mammary glands.  
Neutrophil populations in the tissues were determined by the MPO assay (5, 39) and showed 
no difference between the primiparous and virgin groups. Analysis by real-time RT-PCR of 
B220, a B-lymphocyte’s marker, also demonstrated no difference between the two groups. 
Although a microarray study found higher levels of immunoglobulin gene expression after 
involution compared with virgin mice (10, 42) the results of immunohistochemical staining 
of a B-cell marker showed no obvious changes in the B-cell number even in mammary 
glands at early stages of involution (42). Taken together, these results suggest that although 
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the number of B-cells does not increase in the mammary gland after involution is completed, 
some immunoglobulin genes are still more active than in the virgin gland.  
We also tested the levels of several mRNAs, namely IGF-I, Lbp, Mmp12, Spp1, 
Tgfβ3 and SGP2, in the virgin and parous glands. These genes all showed altered expression 
between involuted and virgin mammary glands of mouse (10). Among them, Lbp, Mmp12 
and Spp1 also showed higher expression in parous mammary glands than in virgin glands of 
rat in a recent microarray study (44). We found higher expression of Lbp, Mmp12 and Spp1 
in the fully involuted mammary gland but we did not find differences in expression levels of 
IGF-I, Tgfβ3 and SGP2. Several differences between our results and D’Cruz’s may be 
responsible for our lack of agreement.  Some possibilities are 1) experimental animals (rat vs. 
mouse), 2) method (real-time PCR vs. microarray), 3) estrous stage of animals (diestrous vs. 
not determined), or 4) an infection in one of the glands in the parity pool for the microarray. 
We found higher expression of several macrophage markers (Mpeg1, CD14 and 
Emr1 (F4/80)) in mammary glands of primiparous compared with virgin rats. This result was 
also observed in the mouse (10).  We confirmed the result by immunohistochemical staining 
of the macrophage marker, CD68. The increased macrophage population in the parous 
mammary gland may be macrophages that have remained in the gland beyond involution.  
Although not supported by earlier studies (23, 34) more recent studies have shown that the 
number of macrophages in the mammary gland increases during involution (3, 21, 42).  Thus, 
it appears that macrophages enter the mammary gland during involution and a subset remains 
in the gland even after 28 days of involution in the rat when the mammary gland is 
considered to be fully involuted.  
While parity protects against the occurrence of breast cancer, it is positively 
associated with increased aggressiveness of cancer and decreased survival rates (2, 9, 20, 22, 
45).  These studies showed a large increase in cancer aggressiveness in breast cancer of 
parous compared with nulliparous females within about 6 years of parturition.  Although 
most studies did not show a measurable effect of parity on tumor aggressiveness later in life, 
at least one study found an association of axillary lymph node involvement with parity in 
women with 4 pregnancies or more and this association was strongest with older women  
(22).   
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The association of parity with increased aggressiveness of breast could be explained 
by the presence of larger numbers of macrophages in the mammary gland after parturition 
because macrophages are capable of being converted from the protective M1 macrophage to 
the tumor promoting M2 macrophage. Macrophages  remaining in the mammary gland after 
pregnancy would contribute to creating a different microenvironment in the tissue than is 
present in the virgin gland.  It has been argued that the reason for a higher frequency of more 
aggressive cancers after pregnancy is that a wound healing and inflammatory 
microenvironment is established in the mammary gland during involution and that this 
microenvironment is conduce to the proliferation of tumor cells (38).  The macrophage is a 
component of both wound healing and inflammatory microenvironments and is the one 
immune cell type that is elevated in parous compared with age-matched virgin mice, 
Studies of the effects of hormonal treatments on the susceptibility to breast cancer 
have lead to proposals that the extent of differentiation of the epithelium in parous glands is 
greater than in virgin glands (35).  This proposal was supported by the finding that p53 is 
required to observe the effect of parity on carcinogen-induced breast cancer (24, 41).  
However, p53 was not amongst the genes found to be differentially expressed in the parous 
compared with the virgin breast (10).  Our finding of an increased number of macrophages in 
the parous gland is compatible with the hypothesis that epithelial differentiation is more 
complete in the parous gland and that, although p53 is required for differentiation to occur, 
the driving force is the increased size of the macrophage population.  Macrophages are 
known to be associated with the terminal end buds and to promote differentiation of the 
mammary epithelium (15, 17). 
During mammary gland involution, a local inflammatory response occurs in the 
absence of infection (28, 42). Lcn2 is an acute phase protein (APP) with high expression in 
the mammary gland and uterus during involution (37).  Its expression in the fully involuted 
mammary gland of primiparous rats is higher than in virgin rats. Lcn2 is expressed by 
epithelial and hematopoietic cell types and induces apoptosis in neutrophils but not in 
macrophages (11). The persistently high expression of Lcn2 in involuted mammary gland 
may be a reason that more macrophages but not neutrophils remain after involution is 
complete.  We compared the relative expression of macrophage marker,  Emr, and Lcn2 in a 
 64 
 
variety of tissues of primiparous and virgin animals and found that the expression of Emr1 is 
higher in parous compared with virgin mammary glands, but not in other reproductive tissues 
nor in liver. Lcn2 is highly expressed in these tissues on toxic or endotoxin challenge (liver) 
or during involution (uterus) or throughout the ovarian cycle (ovary).  The similar 
proportional expression patterns of Emr and Lcn2 in parous compared with virgin animals 
suggests a relationship.   
Parity also provides protection against endometrial cancer and ovarian cancer in 
humans as it does for breast cancer (13, 16, 19, 25, 31-33). We propose that the protection 
against breast cancer provided by parity may be due to the increased immune surveillance 
caused by the increased macrophage population in rat mammary gland after parity. However, 
we did not find more macrophages in rat uterus and ovary after parity.  This may imply that 
increased immune surveillance provided by macrophage is not a universal protective factor 
against cancer in different organs after parity and may not be the only mechanism for the 
protection. However, the lack of evidence of protection against endometrial cancer and 
ovarian cancer provided by parity in rats makes it difficult to relate our results for these 
tissues to the results of studies of endometrial and ovarian cancers in women.  
In summary, we have found that the number of macrophages is increased in the 
completely involuted primiparous rat mammary glands compared to age-matched virgin 
glands. The resulting increased immune surveillance in the mammary gland may play a role 
in the protective effect of parity against breast cancer.  The higher frequency of macrophages 
in the parous gland may also be responsible for the observed positive association of parity 
and more aggressive breast cancers. 
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2.8  FIGURES 
Figure 1.  Macrophage gene expression is higher in primiparous mammary glands 
compared with age-matched virgin glands.  Total RNA from mammary glands of rats were 
analyzed by Northern blot (SGP-2) and real-time RT-PCR (others).  mRNA of target genes 
were normalized to reference gene GPDH (Northern blot) or Cyclophilin (real-time PCR) of 
the same sample. P: primiparous, V: age matched virgin.  14 parous rats and 9 virgin rats 
were used to obtain the data. 
Figure 2. Macrophage-specific elevation of hematopoietic cell markers in parous 
mammary glands. Representative markers were tested to determine the population densities 
of immune cells in the mammary glands of primiparous rats and virgin rats.  Real-time RT-
PCR was used to detect macrophage marker Emr1 and B cell marker B220. The results were 
normalized to the level of cyclophilin in the same sample. Neutrophils were detected by the 
MPO assay. The error bars shows the standard error of the mean. * indicates p<0.05. Mac: 
macrophage, Neu: neutrophil, P: primiparous, V: age-matched virgin.  
Figure 3.  More macrophages found in parous compared with virgin mammary glands. 
A: immunohistochemical staining with CD68 of a paraffin-embedded tissue section from a 
rat mammary gland with 1000x magnification. B: macrophages were counted from randomly 
selected 10 fields with 400x magnification of each section. The total number of macrophages 
of the ten fields was used for analysis. Error bars are the standard errors of the mean from 6 
primiparous samples and 8 virgin samples respectively. p<0.01. 
Figure 4.  Selective increase in macrophage gene expression in mammary glands of the 
parous rat. Total RNA from liver, uterus, ovary and mammary gland of rats were analyzed 
by real-time RT-PCR for Emr1 and Lcn2. The values are the Emr1 or Lcn2 mRNA 
normalized to cyclophilin mRNA of the same sample. P: primiparous, V: age matched virgin. 
14 primiparous and 9 virgin rats were used in the experiment. error bars show the standard 
error of the mean. * indicates p<0.05. 
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Table 1.  Expression of genes in rat mammary gland after weaning 
gene P/V std p value 
Emr1 2.79 2.54 0.003* 
SPP1 2.57 2.75 0.030* 
IL-6 2.07 1.61 0.015* 
**Mmp12 2.05 1.70 0.027* 
**Mpeg1 1.95 1.37 0.010* 
Lbp 1.90 1.50 0.017* 
Lcn2 1.68 1.05 0.021* 
CD14 1.52 0.92 0.042* 
SGP-2 0.95 0.41 0.670 
IGF-I 0.88 0.41 0.520 
Tgfb3 0.52 0.62 0.150 
 
Total RNA from mammary glands of primiparous (P) and age matched virgin (V) 
rats were analyzed by Northern blot (SGP-2) and real-time RT-PCR (others).  mRNA 
of target genes were normalized to reference gene GPDH (Northern blot) or 
Cyclophilin (real-time PCR) of the same sample. 14 parous rats and 9 virgin rats 
were used to obtain the data. Genes expressed by macrophages are in italic. *: 
p<0.05; **: macrophage specific 
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CHAPTER 3.  MYCOPLASMA INFECTION PRODUCES AN 
INFLAMMATORY STATE OF GENE EXPRESSION IN MAMMARY 
EPITHELIAL CELLS INVOLVING ACTIVATION BY NF6B, C/EBP 
AND I6Bζ　 
A paper to be submitted to Infection and Immunity 
 
Wei Zhao1,2, Lee Bendickson1 and *Marit Nilsen-Hamilton1,2* 
1Department of Biochemistry, Biophysics and Molecular Biology and the 
2Interdepartmental Molecular, Cellular and Developmental Biology Program, Iowa State 
University 
 
3.1  ABSTRACT  
Mycoplasma infection causes inflammation of epithelial tissues in vivo and is a 
common problem of cell cultures.  Epithelial cells are the first responders to microbial 
infection when they mount the innate immune response.  To understand how mycoplasma 
infection might influence epithelial cell signaling and gene expression, we investigated the 
effect of M. arginini on mammary epithelial (HC11) cells.  Unlike other bacteria, 
mycoplasmas do not produce the lipopolysaccharides (LPS) that are responsible for 
activating many signal transduction pathways through TLR receptors.  However, 
macrophage-activating lipopeptide-2 (MALP-2) a mycoplasmal membrane lipopeptide 
stimulates TLR2/6 and activates downstream genes in immune cells.  Here we show that the 
expression levels of three genes encoding proteins secreted during the innate immune 
response (Lcn2, IL-6 and TNFα) are elevated in M. arginini -infected cells.  Expression of 
these genes was also increased in response to MALP-2.  Investigating the mechanism of 
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MALP-2 action, we demonstrated that MALP-2 induces NFκB, C/EBP and IκBζ. The same 
changes in gene expression were observed in response to LPS, but with different kinetics.  
Activation of the Lcn2 promoter requires both NFκB and C/EBP.  Selective reduction of 
IκBζ by shRNA reduced Lcn2 promoter activation by MALP-2.  Lcn2 gene expression was 
persistently activated for at least 72h after adding MALP-2 and was elevated by about 100-
fold in cells chronically infected by M. arginini.  Thus, mycoplasma contamination can 
significantly change the gene expression pattern of epithelial cells, creating a condition that 
resembles their activation during the innate immune response.   
 
3.2  INTRODUCTION 
Infections by pathogenic mycoplasma can induce inflammation in the host (20, 23, 36, 
39).  When stimulated by mycoplasmas or extracts of mycoplasma membranes murine 
macrophages and human monocytes produce proinflammatory cytokines and chemokines, 
including intenleukin-1 (IL-1), IL-6, tumor necrosis factor (TNFα), and prostaglandins, as 
well as nitric oxide (NO) (1, 11, 31, 40).  The most relevant mycoplasmal components for 
activating the early host inflammatory reaction are the mycoplasmal lipoproteins and 
lipopeptides (24).  Macrophage activating lipopeptide-2 (MALP-2) is a lipopeptide extracted 
from Mycoplasma fermentans (M. fermentans) with the sequence (S-[2,3-bisacyl-
(C16:0/C18:0;C18:1)-oxypropyl]cysteine-GNNDESNISFKEK (29, 30).  The responses of 
host or cultured macrophages to MALP-2 are similar to their responses to the bacterial 
endotoxin, lipopolysaccharide (LPS), and include the production of proinflammatory 
cytokines and chemokines such as IL-6 and TNFα  (7, 10, 43).  However, while LPS signals 
mainly through TLR4, MALP-2 utilizes TLR2 and TLR6 (22, 28, 37, 41).   
Epithelial cells in vivo are generally the first responders to many pathogenic bacteria.  
These cells respond with increased levels of the transcription factors NFκB and C/EBP and 
their regulators such as IκBζ (also called MAIL, “molecule possessing ankyrin-repeats 
induced by lipopolysaccharide” or INAP, “IL-1-inducible nuclear ankyrin-repeat protein”) is 
induced by pathogens (12, 21, 44).  This inflammatory response aids in the resolution of 
infection.   
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Mycoplasmas are difficult to detect in cell cultures because they often do not 
substantially affect the growth rate or cell morphology.  Consequently, about 30% of cell 
lines are contaminated with mycoplasmas (16, 42).  Among the more than 100 mycoplasma 
species, only 5 species, most of human or bovine origin, account for more than 95% of cell 
culture contaminations (3, 26, 34, 38).  Although often not detected in cell cultures, 
mycoplasma can have profound effects on cells such as increasing their resistance to killing 
by 5-FUdR and 5-FU (15), degrading extracellular amyloid-beta peptide (45) and inducing 
differentiation of dendritic cells (5). 
HC11 epithelial cells have been used as a cell culture model for differentiated 
mammary epithelial cells because they have many characteristics that identify them as 
lactogenic mammary epithelial cells (2, 13).  We show here that mycoplasma infection of 
HC11 epithelial cells in culture induces a response similar to that observed in the innate 
immune response with activation of the primary response genes, NFκB, C/EBP and IκBζ, 
and a representative secondary response gene, Lcn2. The results of our studies show how 
profoundly gene expression can be altered by mycoplasma infection and that the gene 
expression response in epithelial cells is similar to that in myeloid cells and typical of the 
innate immune response.  We also show that the mycoplasmal product, MALP-2, mediates at 
least some of its effects on host gene expression by regulating the expression/activity of 
NFκB, C/EBP and IκBζ in epithelial cells.  
 
3.3  MATERIALS AND METHODS 
Materials and Cell Culture 
HC11 cells, obtained from Dr. L. Sheffield (University of Wisconsin, Madison, 
Wisconsin) with permission of the line’s originator, Dr. B. Groner (Institute for Experimental 
Cancer, Freiburg, Germany) (2), were cultured in RPMI 1640 media (Sigma, St. Louis, MO) 
with 2% FCS (Hyclone, Logan, UT), 5µg/ml insulin (Sigma, St. Louis, MO), 10 units/ml 
each of penicillin and streptomycin with 5% CO2.  LPS (Sigma) and MALP-2 (Axxora, San 
Diego, CA) treatments were in the same medium but with 0.1% FCS.  HC11 cells were 
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seeded in 6–well plates cultured for 24 h in 2% FCS culture medium and then switched to 
0.1% FCS culture medium.  Sixteen hours later, LPS, MALP-2 or vehicle control were added 
to the medium.  Cells were harvested at various times for RNA or protein analysis.   
Mycoplasma Detection, Removal and Reinfection 
Genomic DNA, prepared using DNAzol (Invitrogen, Carlsbad, CA), was used as 
template in PCR to detect mycoplasma. The primers in this reaction corresponded to a region 
of the 16S rDNA that is highly conserved in mycoplasma (4).  The primer sequences were: 
sense ACCATGCACCAYCTGTCAYTC and anti-sense GAGCAAACAGGATTAGATAC.  
An internal reference control was included with every sample from which a band of 120 bp 
was amplified. The samples were amplified for 28 cycles of 94 EC for 30 sec, 55 EC for 60 
sec, then 72 EC for 60 sec.  A band of 280 bp indicates mycoplasma contamination (4).  This 
band, and another region of the mycoplasma 16S rDNA were sequenced and the 
mycoplasmal contaminant was found to be M. arginini. 
Cell cultures were cleaned of M. arginini by treating the cells with three cycles of 10 
:g/ml BM-cyclin 1 (Roche Applied Science, Indianapolis, IN) for 3 days followed by 5 
:g/ml BM-cyclin 2 (Roche) for 4 days.  The cells were reinfected with M. arginini by 
exposing them to conditioned medium collected from an M. arginini infected cell culture that 
had been filtered through 0.22 µm sterilized filter.  The reinfected cells were transferred for 
three passages before the M. arginini could be detected by PCR. 
Total RNA Extraction and real-time RT-PCR 
Total RNA was extracted by using the Trizol Reagent (Invitrogen) according to the 
manufacture’s instruction.  The samples of total RNA were dissolved in DEPC-treated H2O, 
quantified by spectrophotometry and stored at -80oC until use.  Reverse transcription was 
done after treating 1 µg total RNA with 1 unit DNase (Invitrogen) for 15 min and 
inactivating the DNase by exposure to 70 0C for 15 min. The reverse transcription was done 
with Superscript II (Invitrogen) with an 18 nt oligo dT as primer. The real-time PCR was 
done in an Opticon (MJ research, Waltham, MA) using the FullVelocity™ QPCR Master 
Mix (Stratagene, La Jolla, CA).  Cyclophilin was used as the reference gene to normalize 
gene expression from different samples.  Primers used in the experiments were 1) mouse 
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Lcn2 sense: AATGTCACCTCCATCCTGGTCA, anti-sense: GCGAACTGGTTGTAGTCC-
GTGGT; 2) cyclophilin sense: CTTTTCGCCGCTTGCTGCA, anti-sense: ACCACCCTG-
GCACATGAATCCT; 3) IL-6 sense: GAGGATACCACTCCCAACAGACC, anti-sense: 
AAGTGCATCATCGTTGTTCATACA; 4) TNFα sense: CATCTTCTCAA-
AATTCGAGTGACAA, anti-sense: TGGGAGTAGACAAGGTACAACCC; 5) IκBζ sense: 
TGCAGAGGAATCGGCAGTCT, anti-sense: CGGACTGCGTCCAACTGTGT; 6) 
exogenous IκBζ sense: CACCGCCCTCCATGTTGCT,  anti-sense: GCAAACAACAGAT-
GGCTGGCA; and 7) eGFP sense: ACAAGCAGAAGAACGGCATC, anti-sense: 
ACGAACTCCAGCAGGACCAT. For each analysis a standard curve was used to determine 
the quantity of cDNA in each tested sample.  The standard curve was created by amplifying, 
under the same conditions as the cell-derived samples, a range of known amounts of PCR 
amplicons (from 10-6 to 8 pg/well) using a template with the same sequence as present in the 
cDNA being quantified.  Standard curves were plotted as log(pg/well) vs. C(t).  Samples with 
C(t)’s outside the range of the standard curve were not included in the quantitative data and 
appropriate dilutions of the cDNA were retested to obtain quantitative values within the 
range of the standard curve. Triplicate samples were quantified for each RNA preparation 
and the average of the three values was taken as the value for the RNA preparation. 
Luciferase Expression Vectors and Assay 
Mouse Lcn2 promoters of various lengths were prepared as PCR products from a 
mouse genomic BACmid (ES17526, Genomesystems Inc.) template.  Fragments were 
inserted into the luciferase reporter plasmid pGL3-basic (Promega, Madison WI).  Primers 
used for the various truncations were 1) -2108bp, sense: CAGACACAACAGAAGAGGG-
CAT, 2) -1477bp, sense: TGTGGGTTGTGTGAGGCTGTA, 3) -1003bp, sense: CAGGGC-
AGTGTGGAGACACA, 4) -711bp, sense: GCAGCCACATCTAAGGACTACG, 5) -438bp 
sense: GGTCTGGTGTTCAGATGGCTT), 6) -253bp sense TGCCTGCCAGAATCCAAAG, 
7) -197bp, sense: CAGCCCTTCCTGTTGCTCA, 8) -108bp, sense: GCAATTACTTCATG-
GCTTCCTG, 9) -253-NFκB,GGG/AAA: sense: TGCCTGCCAGAATCCAAAGC-
CCTAAAAATG with the same anti-sense oligonucleotide starting at +53 bp used for all: 
GGTTTCCACAGCTACTAGGTCTGA.  Mutagenesis of the promoter was done using the 
 80 
 
Quickchange II kit (Stratagene) to convert the C/EBP binding site from CAGCCCTTCC-
TGTTGCTCAACCTTGCACAGTTCCGAC to CAGCCCTTCCTGGCACTTGGCCTTGC-
ACAGTTCCGAC in which the changed bases are underlined.   
To measure the relative activities Lcn2 and other promoters, HC11 cells were co-
transfected, using Lipofectamine 2000 (Invitrogen), with the appropriate promoter-luciferase 
reporter plasmids in combination with the plasmid pRLSV-40 (Promega) from which the 
Renilla luciferase is expressed from the SV40 promoter.  The activities of the two luciferases 
were quantified by the Dual Luciferase assay (Promega) using a Glomax 20/20 luminometer 
(Promega).  The Renilla luciferase activity provides an internal control for cell lysate content 
of the sample and to obtain a measure of promoter activity.  For each sample, the value for 
the firefly luciferase activity was divided by that for the Renilla luciferase activity. Triplicate 
samples were quantified for each cell lysate and the average of the three luciferase ratios was 
taken as the value for the cell lysate. 
IκBζ Silent Mutation 
IκBζ cDNA was amplified from a preparation of HC11 RNA and was cloned into 
pcDNA3.1(-) (Invitrogen). A silent mutation in the region that is complementary to shIκBζ 
in the wildtype mRNA was created using the Quickchange II kit (Stratagene) to convert the 
sequence GCCCTGCTTCAGAATATTATA to GCCCTGCTCCAAAACATTATA in which 
the changed bases are underlined. 
 
3.4  RESULTS 
Higher Expression of Inflammatory Response Genes in M. arginini -
Infected Cells 
The discovery of a mycoplasma-infected HC11 cell line in our laboratory provided 
the opportunity of investigating the effect of mycoplasma contamination on epithelial cells 
and on the expression of genes that are activated during the innate immune response in these 
cells.  The mycoplasma was identified as M. arginini by the sequence of its 16S rDNA and 
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the cells were freed of M. arginini with a BM-cyclin regime.  A newly infected cell subline 
was then created using filtered conditioned medium from the parent infected cells.  All cell 
sublines exhibited similar epithelial-type morphology and growth rates (Fig. 1A,B).  The 
infection status of each cell subline was verified by PCR (Fig, 1C) 
The levels of expression of three genes that respond to bacterial infection during the 
innate immune response (Lcn2, TNFα, and IL-6) were determined by real-time RT-PCR.  
All three genes were expressed at much higher levels in the two cell sublines that were 
infected with M. arginini (Fig. 1D).   
Gene Expression Induced by LPS or MALP-2 
Mycoplasma do not produce LPS, but they release a lipopeptide, MALP-2, with a 
similar ability to LPS to induce the expression of IL-6 and TNFα in macrophages (7, 10, 43).  
Both LPS and MALP-2 increased the expression of IL-6 and TNFα in mycoplasma-free 
HC11 cells.  Whereas the kinetics of the IL-6 responses to MALP-2 and LPS were similar, 
TNFα gene expression responded to MALP-2 with a peak at least 1 h earlier than for LPS 
(Fig. 2).   
Lcn2, which was more than 100-fold increased in its expression with M. arginini 
infection, was also tested for its response to MALP-2 and LPS.  Unlike for IL-6 and TNFα, 
Lcn2 expression persistently increased over the course of at least 72 h (Fig. 3).  This 
persistent increase in Lcn2 gene expression in response to MALP-2 is consistent with the 
observed high levels of Lcn2 expression in M. arginini-infected cells. 
High Sensitivity of Lcn2 Expression to MALP-2  
MALP-2 is reported to be a potent macrophage stimulatory lipopeptide that 
stimulates NO release from macrophages at concentrations in the picomolar range (30).  To 
determine the sensitivity of epithelial cells to MALP-2, we performed a dose response study 
of MALP-2 activation of Lcn2 expression in mycoplasma-free HC11 cells.  The half-
maximal response of MALP-2 on Lcn2 expression in HC11 cells was determined from an 
average of four independent experiments to be 320 pM by using a nonlinear fit model (R2 
0.96) (Fig. 4).  These data show that epithelial cells are stimulated by the same concentration 
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range of MALP-2 that activates macrophages. Thus, in vivo, it is expected that both epithelial 
cells and macrophages are activated by MALP-2 during an M. arginini infection. 
NFκB and C/EBP DNA Elements are Necessary For M. arginini and 
MALP-2 Induced Lcn2 Expression 
To investigate the mechanism by which MALP-2 and M. arginini regulate Lcn2 
expression we used an Lcn2 promoter driving the expression of a luciferase reporter system.  
A comparison of reporter activity of a range of truncated Lcn2 promoters showed that the 
shortest length of promoter to respond to M. arginini infection was a 253 bp fragment that 
contains the NFκB and C/EBP elements (Fig. 5). The NFκB and C/EBP elements in the Lcn2 
promoter are important for Lcn2 expression induced by IL-1β and LPS (6, 25).   
To test if one or both NFκB and C/EBP elements are required for promoter 
responsiveness to M. arginini infection, reporter plasmids were constructed in which one or 
both sites were mutated to sequences known not to be bound by the respective transcription 
factor. These reporter genes were transfected into mycoplasma-free and M. arginini-infected 
cells.  The mycoplasma-free cells were also stimulated by MALP-2 to determine the 
requirement for one or both elements for the MALP-2 response.  The results showed that 
both NFκB and C/EBP elements are required for MALP-2 or M. arginini activation of the 
Lcn2 promoter (Fig. 6).   
IκBζ is a MALP-2 Downstream Regulator of Lcn2 Expression 
IκBζ is a nuclear member of the IκB family that is reported to cooperate with NFκB 
in activating gene expression.  It has been shown to regulate Lcn2 gene expression in 
response to LPS in macrophages (19).  In Figure 7 it is shown that both MALP-2 and LPS 
induce IκBζ mRNA which peaked 1 h after addition of MALP-2 and 2 h after addition of 
LPS (Fig. 7). These time courses parallel those for stimulation of IL-6 and TNFα by MALP-
2 and LPS (Fig. 2), suggesting a common mechanism of activation for these three genes.   
IκBζ has been shown to be important for regulating secondary response but not 
primary response genes.  Therefore we tested whether IκBζ is involved in the activation by 
MALP-2 of the secondary response gene, Lcn2.  To do this, we used shRNA (short hairpin 
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RNA) targeted to IκBζ (shIκBζ).  To test for the specificity of the shIκBζ in targeting IκBζ 
mRNA, we created two control plasmids, one that expressed IκBζ mRNA and the other that 
expressed a mutated IκBζ mRNA in which a silent mutation was introduced into the region 
complementary to the shIκBζ (mIκBζ).   We found that expression of the IκBζ mRNA but 
not the mIκBζ mRNA was knocked down by shIκBζ (Fig. 8 inset).  
The activity of the 253 bp Lcn2 promoter was decreased by 60% when shIκBζ was 
used to knock down the expression of IκBζ in HC11 cells stimulated by MALP-2 (Fig. 8). 
Overexpression of either IκBζ or mIκBζ overcame the inhibition of MALP-2-induced Lcn2 
promoter activity by shIκBζ.  As expected, expression of the mIκBζ, which is not suppressed 
by shIκBζ, resulted in higher activity of the Lcn2 promoter activity compared to that with 
IκBζ expression (Fig. 8). 
 
3.5  DISCUSSION 
As an externally exposed tissue, the mammary gland is susceptible to bacterial 
infection, which results in mastitis, an inflammatory condition that has been studied 
extensively in agricultural animals because of its large economic impact.  Infections by 
pathogenic mycoplasma can also induce host inflammation (20, 23, 36, 39). Tissue-resident 
macrophages and dendritic cells (DCs) recognize the infection when prokaryotic-derived 
molecules referred to as PAMPs (pathogen associated molecular patterns) are recognized by 
pattern recognition receptors such as the Toll-like receptors (TLR).  Relevant to this 
discussion are the mycoplasma-derived MALP-2, which signals through TLR2 and TLR6, 
and gram negative bacterial-derived LPS, which signals through TLR4 (22, 28, 37, 41). 
Activation of TLRs results in the release proinflammatory cytokines and other inflammatory 
mediators (27, 32).   
The TLRs are expressed on macrophages, dendritic cells, mast cells and epithelial 
cells including on mammary epithelial cells (9, 14, 35).  Our results show that M. arginini 
infection, MALP-2, and LPS stimulate the expression of genes that are activated by PAMPs 
and that are induced in epithelial cells during the innate immune response.  Although both 
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MALP-2 and LPS activated the expression of the same three primary response genes (IL-6, 
TNFα, and IκBζ), the kinetics of changes in TNFα and IκBζ mRNAs were different for LPS 
and MALP-2 treatment, with the MALP-2 response peaking 1 h earlier than for LPS.  This 
observation suggests that the mechanism leading to increased expression of these two genes 
differs between LPS and MALP-2.  Indeed, it is known that TLR4/6 and TLR2 signaling 
differs with both utilizing the MyD88-driven activation of NFκB, but only TLR4 signals 
through IRF3 (33).  The kinetics of TLR4 activation by LPS is delayed in macrophages in the 
absence of MyD88 (18).  Therefore, a low level of MyD88 may be responsible for the 
difference in response kinetics to MALP-2 and LPS in HC11 cells.  Although MyD88 has 
been reported to be expressed in epithelial cells, its expression level in HC11 cells is not 
known.   
In addition to testing the effects of MALP-2 on three primary response genes in HC11 
cells (IL-6, TNFα, IκBζ), the ability of MALP-2 to activate a secondary response gene, Lcn2, 
was also tested.  By contrast to the faster response of TNFα and IκBζ, the kinetics of the 
response of Lcn2 to MALP-2 appeared slower than to LPS.  In addition the response to both 
activators persisted over 72 h with a secondary increase appearing to begin between 48 h and 
72 h after addition of the stimulus.  This persistent increase was not observed for TNFα and 
IL-6, both of which are also regulated by C/EBP and NFκB as we have shown here for Lcn2.  
Instead the persistent increase may be related to the increase in IκBζ, which has recently 
been shown to activate secondary response genes but not primary response genes in 
macrophages and macrophage cell lines (19). LPS stimulates a MYD88-dependent 
trimethylation of H3K4 histone on the Lcn2 promoter, which is proposed to stabilize its 
activated state (19).  By contrast, H3K4 histone methylation was constitutively high on the 
promoters of two primary response genes.  These authors also implicated IκBζ in the 
mechanism by which LPS activated the Lcn2 promoter by showing that the increase in 
histone trimethylation on the Lcn2 promoter was lost in bone marrow macrophages from 
Nfkbiz-/- mice (19). 
We tested the hypothesis that, as for myeloid cells in response to LPS, IκBζ might 
also be involved in the MALP-2 regulation of Lcn2 expression in epithelial cells.   Two lines 
of evidence from the studies reported here are consistent with this hypothesis.  First MALP-2 
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induces expression of IκBζ before the maximal increase in Lcn2 is observed.  Second, 
shRNA that selectively decreased the expression of exogenous IκBζ also decreased Lcn2 
expression levels.  The results of these experiments demonstrate that IκBζ mediates the 
regulation of Lcn2 by MALP-2 as has been shown previously for LPS.  In monocytes, LPS 
regulates Lcn2 gene expression by histone trimethylation, mediated by MyD88, and through 
IκBζ by promoting nucleosome remodeling (19).  These events of chromosome remodeling 
may also be downstream of MALP-2 and may be responsible for the persistent activation of 
this gene in response to this stimulus. 
Our results show that M. arginini and the mycoplasma membrane lipopeptide MALP-
2 induce expression of primary and secondary response genes of innate immunity.  The 
mechanism of induction in mammary epithelial cells is similar to that in myeloid cells in that 
it requires both NFκB, C/EBP and IκBζ. This result is in contrast to the activation of Lcn2 in 
Sertoli cells, another epithelial cell type, in which Lcn2 gene expression is regulated by an 
NFκB-dependent, IκBζ-independent mechanism and is not induced by the inflammatory 
signals LPS and IL-1β (8).  
MALP-2 is active in stimulating Lcn2 at picomolar levels and is thus a very potent 
inflammatory signal.  The dose dependence of the epithelial response to MALP-2 is very 
similar to the response of macrophages and supports the assumption that the same TLRs are 
involved in the response in both cell types (30).  The persistent activation of Lcn2 in these 
epithelial cells even after a single treatment with MALP-2 is consistent with the persistent 
inflammatory response to mycoplasma observed for mammary inflammation due to 
mycoplasma infections in vivo (17).  
As well as providing the experimental basis for a mechanistic hypothesis to explain 
the prolonged activation of Lcn2, and perhaps of other secondary response genes that are 
activated in epithelial cells during the innate immune response, our results also provide an 
important reminder that mycoplasma contamination of cell cultures can drastically alter their 
gene expression profiles without significantly affecting the cell proliferation rate or cell 
morphology.   
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3.8  FIGURES 
Figure 1.  M. arginini infection does not affect growth rate or morphology of HC11 cells.  
HC11 cells infected, cleaned or cleaned and reinfected with M. arginini were tested for the 
levels of expression of key inflammatory response genes.  A. HC11 cells that were 1) 
infected with M. arginini (myco+), 2) cleaned of M. arginini (myco-), or 3) cleaned then 
reinfected with M. arginini (reinfected) were seeded on 10 cm plates. Pictures were taken 48 
h after seeding.  B. HC11 cells were seeded in 24 well plates. Cells were counted after 
different time points. Shown are the means ±standard deviations (SD) from duplicate wells 
at each time point from a representative experiment. C. Genomic DNAs isolated from the 
different cell cultures were amplified with primers targeting the 16S rDNA of mycoplasma. 
PCR products were run in 2% agarose. The mycoplasma DNA was amplified from M. 
arginini infected cell cultures (myco+ and reinfected) but not the mycoplasma-free cell 
culture.  D. The expression levels of Lcn2, IL-6 and TNF" and cyclophilin were quantified 
by real-time RT-PCR. The relative mRNA levels in all samples were normalized to those in 
cleaned cells. Shown are the mean ± SD from two independent experiments. Myco-: cleaned 
HC11 cells, myco+: M. arginini infected HC11 cells, re-infected: HC11 cells cleaned then 
reinfected with M. arginini. 
Figure 2. IL-6 and TNF" mRNAs are induced by LPS and MALP-2. Mycoplasma-free 
HC11 cells were treated with LPS (10 :g/ml) or MALP-2 (10 ng/ml) for the indicated time 
periods. IL-6, TNF" mRNAs and cyclophilin were quantified by real-time RT-PCR. For 
each treatment set, the time zero point was used to normalize each set of results at all time 
points. Shown are the means ± SD from two independent experiments.  
Figure 3. Persistent increase in Lcn2 expression induced by LPS and MALP-2.  
Mycoplasma-free HC11 cells were treated with LPS (10 :g/ml) or MALP-2 (10 ng/ml) for 
the time periods shown. Lcn2 mRNA was quantified by real-time RT-PCR. Shown are the 
means ± SD from 2 independent experiments except for the 24 h points, which are the 
average of 3 experiments ± SD. {: no treatment, U: LPS, : MALP-2. 
Figure 4.  Lcn2 gene expression is highly sensitive to MALP-2.  Mycoplasma-free HC11 
cells were treated with MALP-2 at various concentrations over a 12 h period. Lcn2 and 
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cyclophilin mRNAs were quantified by real-time RT-PCR. All values were normalized to the 
average control value from cells treated without MALP-2. Shown are the means ± SD from 
four independent experiments.  
Figure 5.  The region of the Lcn2 promoter that responds to M. arginini lies between -
197 and -253. Cells were co-transfected with a firefly luciferase reporter plasmid containing 
a truncated Lcn2 promoter (each starting at the listed position and ending at +53 bp) and a 
Renilla luciferase expression plasmid. The cells were harvested and measured for luciferase 
activity 48 h after transfection. The relative luciferase activities are shown normalized to the 
value obtained from cells transfected by a plasmid from which firefly luciferase was 
expressed from an SV40 promoter. Shown are the means ± SD from four independent 
experiments for the M. arginini contaminated cells (myco+) and two experiments for the 
mycoplasma-free cells (myco-). Lcn2-1477, Lcn-1003, Lcn2-711 and Lcn2-438 had similar 
activity levels as Lcn2-2108 in M. arginini infected HC11 cells (data not shown).  
Figure 6.  NF6B and C/EBP binding sites are required for MALP-2-induced Lcn2 
expression.  Cells were co-transfected with plasmids with the indicated Lcn2 promoters 
driving firefly luciferase expression and a Renilla luciferase expression plasmid.  Twenty 
four h after transfection the cells were treated with or without 10 ng/ml MALP-2 and then 
harvested and measured for luciferase activity 12 h later. The relative luciferase activities 
were normalized to the SV40 promoter control, which was set at 1. Shown are the means 
± SD from two experiments. Legend: myco-: mycoplasma-free cells; MALP-2: mycoplasma-
free cells treated with MALP-2; myco+: M. arginini-infected cells.  
Figure 7.  I6Bζ gene expression is induced by LPS and MALP-2.  Mycoplasma-free 
HC11 cells were treated with 10 :g/ml LPS or 10 ng/ml MALP-2.  I6Bζ mRNA was 
quantified by real-time RT-PCR and normalized to the 0-time point. Shown are the means ± 
SD from two independent experiments. 
Figure 8.  I6Bζ shRNA targets I6B. mRNA and inhibits Lcn2 promoter activity.   
HC11 cells were cotransfected with the 253bp Lcn2-luciferase plasmid and Renilla-luciferase 
plasmid along with combinations of plasmids to express the following RNAs: SHC002 or 
shI6Bζ plus either I6Bζ or mI6Bζ.  pcDNA3.1 was used as a control plasmid for the I6Bζ 
and mI6Bζ expression vectors.  Cells were treated with 10 ng/ml MALP-2, added 18 h after 
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transfection, and lysed 24 h later.  The lysate was tested for promoter activity by the Dual 
Luciferase assay. Shown are the means ± SD from two independent experiments.  Inset 
shI6Bζ selectively targets I6Bζ mRNA: HC11 cells were co-transfected with eGFP and a 
combination of the following: shIκBζ plasmid or a control shRNA plasmid (Sigma), each in 
combination with the IκBζ or mIκBζ expression plasmids. Samples were collected 24 h after 
transfection and exogenous IκBζ mRNA was quantified by real-time RT-PCR with plasmid-
derived primers that did not amplify the endogenous I6Bζ.  Each value was normalized to the 
level of eGFP mRNA in that sample. Shown are the means ± SD from two independent 
experiments.  
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CHAPTER 4.  GENERAL DISCUSSION AND FUTURE PLANS 
Elevated Macrophage Population Size and Lcn2 Expression in the Fully 
Involuted Rat Mammary Gland 
One of the strongest protective factors for breast cancer is a full term pregnancy early 
in life (early 20s) that gives a 50% reduction of lifetime risk of breast cancer when compared 
with the risk of nulliparous women (Bernstein, 2002; Lambe et al., 1996; MacMahon et al., 
1970). The protective effect of an early full-term pregnancy against breast cancer is observed 
in humans and also in experimental rodent models. Rats and mice that have undergone a full 
term pregnancy also gain protection against chemically induced mammary carcinogenesis 
when compared with nulliparous animals (Russo, 1996; Sinha et al., 1988; Welsch, 1985). 
However, despite the well-documented data, the mechanism of pregnancy/hormone-induced 
protection against breast cancer still remains unclear. One explanation for this protection is 
the increased differentiation status of the parous epithelium (Russo and Russo, 1997).  
However, this does not explain the association of parity with increased aggressiveness of 
breast cancers, particularly cancers that occur soon after pregnancy (Albrektsen et al., 2006; 
Colditz and Rosner, 2006; Largent et al., 2005; Manjer et al., 2005; Whiteman et al., 2004).  
Studies in the mouse showed that more immune cells infiltrate the mammary gland 
during involution (Monks et al., 2002; Stein et al., 2004). However, most studies focused on 
the mammary gland in early stage of involution and only one microarray study indicated that 
some cells of the immune system may stay in the mammary gland after complete involution 
(D'Cruz et al., 2002; Monks et al., 2002; Stein et al., 2004). One possible explanation for the 
protective effect of parity against cancer is increased immune surveillance in the parous 
gland. Consistent with a previously published finding from the mouse mammary gland 
(D'Cruz et al., 2002), I also found that the levels of mRNAs from several genes expressed by 
macrophages were significantly elevated in the primiparous rat mammary gland. I thus tested 
the hypothesis that parity results in an increase in hematopoietic cell types in the mammary 
gland using the diestrous rat as the model.  The rat is the most commonly used rodent for 
reproductive studies and for studies of the effect of parity on breast cancer.  And to my 
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knowledge, there is currently no pubulished evidence to demonstrate a change in the immune 
cell populations in the fully involuted rat mammary gland. My results showed that the 
number of macrophages, but not B cells, T cells or neutrophils, is higher in fully involuted rat 
mammary glands compared with age-matched virgin glands.  
Lcn2 is an acute phase protein for which expression is up-regulated during early 
involution (Ryon et al., 2002). I found that Lcn2 expression in fully involuted rat mammary 
glands is higher than in age matched virgin mammary glands. Lcn2 is expressed by 
hematopoietic cells responding to infection. However, I did not find an increase of two other 
acute phase proteins, SGP-2 and Lbp that also respond to infection in parous mammary 
glands. Thus, the data suggest that the increase in macrophage markers and Lcn2 in the 
parous mammary gland compared to the virgin gland is not a consequence of infection of the 
parous mammary glands. The higher expression of Lcn2 in the parous mammary gland may 
be one reason for the increase of macrophages because Lcn2 has been reported to induce 
apoptosis in neutrophils but not macrophages.  
In summary, I found elevation of both the macrophage population size and Lcn2 
expression in the fully involuted rat mammary gland. The increased macrophage population 
size may provide more effective immune surveillance against arising tumor cells in the 
parous breast.  But, the protective M1-type macrophages can also be converted under the 
influence of tumor cells to the M2-type that promotes tumor aggressiveness.  Thus, an 
increased macrophage population size in the parous breast could explain the dichotomy of 
parity association with decreased cancer incidence and increased cancer aggressiveness. 
Lcn2 and Inflammation 
Inflammation is the response of host tissues to challenges by microbial infections 
including pathogenic mycoplasma (Kennedy and Ball, 1987; Peltier et al., 2003). Tissue-
resident macrophages and dendritic cells (DCs) are believed to mediate recognition of the 
infection through TLRs on their surface, and release proinflammatory cytokines and other 
inflammatory mediators (Mellman and Steinman, 2001; Nathan, 2002). After discovering a 
mycoplasma contaminated cell lines in our lab, I wanted to test whether mammary epithelial 
cells (HC11 cells) can react to mycoplasma infection. As well as being expressed by the 
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immune cells, the TLRs are expressed by epithelial cells including mammary epithelial cells 
(Furrie et al., 2005; Ibeagha-Awemu et al., 2008; Pandey and Agrawal, 2006). I found that 
HC11 cells have the ability to recognize mycoplasma or MALP-2, a mycoplasmal membrane 
lipopeptide, and release proinflammatory cytokines such as IL-6 and TNF-" . Expression of 
Lcn2, an acute phase protein, is also induced by mycoplasma or MALP-2. The role of Lcn2 
in the inflammatory response of HC11 cells to mycoplasma or MALP-2 is not clear. 
However, there are no studies to show mycoplasmas use siderophores to obtain iron. And 
therefore the role of Lcn2 is unlikely to be to restrict iron availability for mycoplasma as has 
been demonstrated E. coli in mice injected i.p. (Flo et al., 2004). In addition, Lcn2 expression 
is increased in some sterile inflammatory diseases such as kidney ischemia-reperfusion injury 
and inflammatory bowel disease (Dooley et al., 2004; Mishra et al., 2006). Thus, Lcn2 may 
be actively involved in the process of inflammation and its resolution.  
I also found NFκB, C/EBP and IκBζ are important for the regulation of Lcn2 
expression during the inflammatory response of HC11 cells to mycoplasma infection or 
MALP-2 treatment. This finding is similar to the regulation of Lcn2 expression by LPS in 
myeloid cells (Cowland et al., 2006; Matsuo et al., 2007; Sunil et al., 2007; Yamamoto et al., 
2004). To our knowledge, this is the first report that IκBζ mediates Lcn2 expression induced 
by MALP-2. However, the mechanism by which IκBζ mediates Lcn2 expression is unknown. 
In summary, my results showed that HC11 cells can recognize and produce an inflammatory 
response to mycoplasma infection or MALP-2. 
Future Plans 
Pathogenic mycoplasma infection can induce a host inflammatory response, during 
which the expression levels of primary and secondary response genes increase. The results of 
this thesis showed that expression of Lcn2, a secondary response gene, induced by MALP-2 
is mediated by IκBζ. A recent study showed that nucleosome remodeling and IκBζ-mediated 
histone H3K4 trimethylation are important for regulation of expression of Lcn2 induced by 
LPS. I would like to test the hypothesis that nucleosome remodeling and histone H34K 
trimethylation are also important for expression of Lcn2 induced by MALP-2. This study will 
help to explain the activation of secondary response genes during mycoplasma infection and 
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contribute to an understanding of mechanisms of the inflammatory response of the host to 
mycoplasma infection. 
I would also like to investigate the relationship of Lcn2 expression and changes in the 
populations of hemopoietic cells during mammary gland involution. The population size of 
both macrophages and neutrophils increases in early involution (Atabai et al., 2007; Clarkson 
et al., 2004; Clarkson et al., 2006; Stein et al., 2007). But I only found an increase in 
macrophages in the fully involuted rat mammary gland. I hypothesize that Lcn2 is the reason 
for there being more macrophages but not neutrophils in the fully involuted rat mammary 
gland, because Lcn2 only induces neutropil apoptosis. By using the Lcn2 knockout and wild-
type mice, we can ask the question of whether Lcn2 expression is a factor that affects the 
population sizes of hemopoietic cells, especially macrophages, in the mammary gland during 
and after involution.  
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APPENDIX DEVELOPMENT OF LIPOCALIN 2 OVEREXPRESSING 
MICE 
Introduction: 
Lipocalin 2 (Lcn2) is a member of the large and diverse lipocalin protein family. 
Members of this family are usually small extracellular proteins that share a common β-barrel 
tertiary structure, which forms a binding site for small hydrophobic molecules (Flower et al., 
2000; Kjeldsen et al., 1996). Lcn2 is found in human (also named neutrophil gelatinase-
associated lipocalin, NGAL), mouse (also named SIP24, 24p3, uterocalin, and siderocalin) 
and rat (also named neu related lipocalin, NRL) (Goetz et al., 2002; Kjeldsen et al., 1994; 
Kjeldsen et al., 1993; Nilsen-Hamilton et al., 1982; Stoesz and Gould, 1995). Lcn2 binds iron 
loaded enterobactin with a KD 0.41 ± 0.11 nM at 20°C (Goetz et al., 2002). By this means, it 
is believed to be bacteriostatic because it reduces iron availability to microorganisms. It is 
thus considered as a component of the innate immune system, which protects the host from 
invasion of bacteria that use enterobactin to acquire iron (Flo et al., 2004; Goetz et al., 2002).  
In order to study the function of Lcn2, I generated Lcn2 overexpressing mice. 
 
Materials and Methods 
Experimental Animals  
All animals were bred and cared for in the Laboratory Animal Facility at Iowa State 
University and were housed under a 12-h light/dark cycle and treated according to current 
NIH guidelines.  Animal care was provided by an animal caretaker and an attending 
veterinarian.  This research was conducted in accordance with the standards set forth in the 
NIH guide for the care and use of laboratory animals.  Animals were sacrificed by CO2 
inhalation before the removal of tissues for the described studies. Prior approval was 
obtained from the Iowa State University Committee on Animal Care for all procedures 
performed on the animals used in these studies.  
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Lcn2 Overexpressing Mice 
Lcn2 overexpressing mice were made by microinjection of a linearized Lcn2 cDNA 
plasmid fragment driven by the human β-actin promoter and the CMV enhancer into 
fertilized eggs. The mice were produced by the Mouse Genome Engineering Facillity, U. of 
Nebraska using DNA constructs provided by me. The genetically engineered mouse strain 
was backcrossed to the BALB/c strain for 6 generations and the mice were tested for 
homogeneity by PCR using genomic DNA as template. The primers for testing Lcn2 
overexpression were sense AGTCGTCGACGACCTAGTAGCTGTGGAAACCATG and 
anti-sense CTAAAGCTTTCAGCCACACTCACCACCCA. The transgenic copy number 
was determined by amplifying with primers of sense TGACAGCAGTCGGTTGGAAGC and 
anti-sense GGCACGAAGGCTCATCATTCA.   
For the transgenic copy number and homozygosity testing, the PCR conditions and 
cycle numbers were adjusted to make sure that all reactions were still in the exponential 
phase. Equal volumes of PCR products, standards and samples, were loaded on an agarose 
gel. Ethidium bromide was used for staining. The picture of the gel was taken and analyzed 
with Image J software (http://rsb.info.nih.gov/ij/). The primers used to screen homozygotes 
were the same as used to identify the transgenic animals.  The ratio of the transgenic band to 
the genomic band was compared to that of a known heterozygous mouse. Mice with 
significantly higher values than the heterozygous mouse standard were identified as possible 
homozygous mice. 
Extraction of Genomic DNA 
A 0.5 cm mouse tail fragment was digested by proteinase K (100 mM Tris-HCl pH 
8.5, 5 mM EDTA, 0.2 % SDS, 200 mM NaCl, 100 µg/ml proteinase K (Invitrogen, Carlsbad, 
CA)) at 54°C overnight. Genomic DNA was precipitated with isopropanol, centrifuged at 
12000 x g at 4°C for 10 min, rinsed with 70% ethanol and centrifuged again. Genomic DNA 
was then dissolved in 1 mM EDTA, 10 mM Tris-HCl pH 8.0.  
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RNA Extraction and Quantitative Real-time RT-PCR 
Tissues were frozen in liquid nitrogen immediately upon removal from the animals, 
and then stored at -80oC. Total RNA was isolated with Trizol Reagent (Invitrogen) following 
the manufacturer's instructions. For reverse transcription, 1 µg total RNA was treated with 
1 unit DNase (Invitrogen) for 15 min at room temperature. After deactivation of the DNase 
with 1 µl 25 mM EDTA and heating at 65 °C for 10 min, the reverse transcription was done 
by using superscript II (Invitrogen), 18 mer oligo dT and dNTP following the manufacturer’s 
instructions. The quantitative real-time PCR (qrt PCR) was done on an Opticon (MJ research, 
Waltham, MA) or a Mini Opticon (Bio-Rad Laboratories, Hercules, CA) with the 
FullVelocity™ QPCR Master Mix (Stratagene, La Jolla, CA). Cyclophilin was used as the 
reference gene to normalize gene expression from different samples. Primers used in the 
experiments were: Lcn2, sense CAATGTCACCTCCATCCTGGTCA, anti-sense 
GCGAACTGGTTGTAGTCCGTGGT; transgenic Lcn2, sense GCCACCACGGACTACA-
ACCAGTT, anti-sense CGCTTCCAACCGACTGCTGTCAC; cyclophilin, sense CTTTT-
CGCCGCTTGCTGCA, anti-sense ACCACCCTGGCACATGAATCCT. 
 
Results 
Development of Lcn2 Overexpressing Mice:  
A diagram of the linearized plasmid used to make the Lcn2 overexpressing mice is in 
Fig. 1A. The transgenic mice were screened by PCR with primers targeting the Lcn2 cDNA 
insertion. However, we found these primers also gave an amplicon from the wild type mouse 
genomic DNA. I found there is a linear relationship between this amplification and the 
amount of genomic DNA used as template. I took advantage of this additional band as an 
internal control to establish the extent to which the DNA samples were amplified. The F1 
mice were of the FVB strain and they were backcrossed to the BALB/c strain for 6 
generations before breeding for homozygotes (Fig. 1B). 
To determine how many copies of the transgenic Lcn2 gene are inserted into the 
mouse genomic DNA, the PCR reaction was used to amplify the transgene with primers 
targeting the β-actin promoter region. Six standards (linearized plasmid diluted in 100 ng 
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mouse genomic DNA) were used to make a standard curve for calculation. The results 
showed that the transgenic Lcn2 gene copy number in the transgenic mouse genome is about 
20 per haploid genomic DNA (Fig. 1C).   
After a homozygous line was established as determined by the PCR test, the 
homozygosity was confirmed by backcrossing with wild type mice and testing the genotypes 
of the pups. The result confirmed the mouse line as homozygous (Table 1).  
Expression of the Transgenic Lcn2 in Different Tissues 
The expression levels of the Lcn2 transgene in various tissues of the transgenic mice 
were tested. Real-time PCR was used to quantify the amount of Lcn2 mRNA. Primers 
targeting the 3’ UTR of the transgene were used to detect the transgenic Lcn2 mRNA. The 
results showed that transgenic Lcn2 mRNA was detected in all tissues from transgenic mice 
but not from wild type mice (Fig. 2A). Heart and lung have the highest transgenic expression 
level, where the ovary and uterus have the lowest. Other tissues have similar expression 
levels. To determine whether the transgenic Lcn2 expression alters the total Lcn2 amount, we 
used primers targeting the Lcn2 coding region to detect both endogenous and transgenic 
Lcn2 expression. The results showed that the change in Lcn2 expression is different among 
the tissues. In tissues such as the colon, intestine, heart, kidney, liver and stomach, the total 
Lcn2 is increased dramatically in tissues from transgenic mouse and Lcn2 was barely 
detectable in these tissues from wildtype mouse. However, in tissues with high endogenous 
Lcn2 expression such as the mammary gland, uterus and ovary, there was no difference in 
total Lcn2 between the transgenic and wildtype mouse (Fig. 2B).   
 
Discussion: 
Several Lcn2 functions have been reported including inducing apoptosis in 
neutrophils, mammary gland epithelial cells and erythroid progenitor cells, preventing 
apoptosis in human MCF7 (a breast cancer cell line), binding siderophores to reduce iron 
availability to microorganisms, promoting epithelial healing in the stomach, promoting or 
inhibiting metastasis of mammary cancer cells (Bong et al., 2004; Devireddy et al., 2001; 
Fernandez et al., 2005; Goetz et al., 2002; Hanai et al., 2005; Miharada et al., 2005; Playford 
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et al., 2006; Tong et al., 2005). However, the range of physiologically significant functions of 
Lcn2 still remains to be defined. For example, the reports regarding the effect of Lcn2 on 
apoptosis are contradictory and more studies are needed to establish a function (Devireddy et 
al., 2005; Devireddy et al., 2001; Tong et al., 2003; Tong et al., 2005).  
The function of Lcn2 relating to iron binding, transport and as a bacteriostatic agent 
of the innate immune system is well accepted. However, the proposed endogenous 
siderophore-like molecule and a signaling Lcn2 receptor has not been identified (Flo et al., 
2004; Goetz et al., 2002). In the human, NGAL protects MMP9 and promotes breast cancer 
metastasis, but the ability to form this covalent bond between NGAL and MMP9 is unique to 
NGAL and not shared by Lcn2 of other species (Fernandez et al., 2005).   
The Lcn2 transgene described here is driven by the human $-actin promoter enhanced 
by the CMV enhancer. We determined that there are about 20 copies of the transgene 
inserted into the transgenic mouse haploid genome in a heterozygous transgenic mouse. The 
transgenic mice were backcrossed to BALB/c strain for 6 generations to have more than 98% 
of the BALB/c background for our experiments. 
The expression of the transgenic Lcn2 gene was tested in ten tissues from 
homozygous and wild type female mice. Transgenic expression was detected in all tissues 
tested. In tissues with very low endogenous Lcn2 expression, such as the colon, intestine, 
heart, kidney, and stomach, the transgenic expression increased Lcn2 dramatically. On the 
other hand, in tissues with high endogenous Lcn2 expression, such as the mammary gland, 
uterus and ovary, the transgenic expression did not appreciably affect the total Lcn2 
expression level. Therefore these mice will be useful for studies in the colon, intestine, heart, 
kidney, liver and stomach because the Lcn2 expression in those tissues increased greatly 
compared to its expression in tissues from the wild type mouse. 
It is also interesting to notice the difference of the total Lcn2 expression in different 
tissues between transgenic and wildtype mice. There are no difference of the total Lcn2 
expression between the groups in mammary gland, uterus and ovary, which are tissues with 
high endogenous Lcn2 expression. Altghou the high endogenous Lcn2 expression may mask 
the transgenic expression so that we won’t see the huge difference between the wild type and 
transgenic mice, but we should still be able to see difference if the transgenic Lcn2 
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expression in these tissues is the same level as in heart or lung. However, we did not see the 
difference. The result also showed that the expression of transgenic Lcn2 is low in uterus, 
mammary gland and ovary. So the high endogenous Lcn2 expression may exert an inhibitory 
effect on the transgenic Lcn2 expression, which may be interesting for future study. 
 
Experiments Conducted 
I used the Lcn2 overexpressing, knockout and wildtype mice to do two experiments. 
However, for both experiments more work needs to be done to confirm the results. I thus did 
not include them in the thesis but give a brief description of the experiments here. 
The first experiment was designed to test the hypothesis that Lcn2 expression is a 
protective factor against breast cancer. Lcn2 knockout and wildtype BALB/c background 
mice were used in this experiment. They were fed 7,12-dimethylbenz(a)anthracene (DMBA) 
via gavage. The mice were monitored for breast cancer incidence. However, due to an 
accidental lapse in the protocol renewal for the experiment, Institutional Animal Care and 
Use Committee (IACUC) of ISU insisted that the experiment be terminated and all animals 
sacrificed. The recorded breast cancer incidence was 7 out of total 29 from the Lcn2 
knockout mice and 5 out of total 35 from the wildtype mice when I terminated the 
experiment. However, more wildtype mice than Lcn2 knocked mice were terminated 
prematurely due to staggered start times.  I also found stomach tumors in 6 out of 29 
knockout mice and in 0 out of 35 wildtype mice by palpation. Subsequent pathological study 
confirmed that they were stomach squamous cell carcinoma. Although the wildtype mice 
may also have had stomach cancers, the tumors were not large enough for me to detect by 
palpation whereas they could be detected in the knockout mice. This finding should be 
further explored with a better designed protocol focusing on stomach cancer. 
The second experiment was designed to test the hypothesis that Lcn2 is a protective 
factor against Salmonella infection because Lcn2 has been shown by others to protect mice 
against infection of E. coli (Flo et al., 2004).  E. coli utilizes enterobactin to obtain iron and 
Salmonella also secrets enterobactin. Therefore, the mouse strains were expected to respond 
similarly to a Salmonella oral challenge as they had been reported to respond to an E. coli i.p 
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challenge.   The result showed that 2 out of 5 Lcn2 overexpressing mice, 3 out of 5 wildtype 
mice and 0 out of 5 Lcn2 knockout mice died by the 6th day after the Salmonella challenge. 
The result is contradictory to the hypothesis and the reported protection of Lcn2 against 
infection of E. coli.  The experiment needs to be repeated with more mice to confirm the 
finding.  
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Figures 
Figure 1. Development of Lcn2 transgenic mice. A: Linearized plasmid. Lcn2 cDNA was 
inserted in the plasmid. Expression was regulated by the CMV enhancer and the human beta 
actin promoter. The picture is from software vector NTI. B: Screening Lcn2 transgenic 
mouse. The primers were designed to amplify the inserted Lcn2 cDNA. The 500 bp band is 
the amplicon from mouse genome DNA and the 663 bp band is from transgenic DNA. wt: 
wild type; tr: transgenic; B: blank. C: The transgenic Lcn2 copy number determination. A 
PCR reaction with primers targeted to the transgenic gene promoter region was used to 
determine how many copies of the transgene were inserted into the mouse genome. Six 
standards, which were the linearized plasmid diluted to various extents in 100ng mouse 
genomic DNA, were used. One hundred nanograms of genomic DNAs from heterozygous 
transgenic mice 4710.27 and 4710.28 were tested. Equal amounts of the PCR products were 
loaded on 1.2% agarose gel. The picture of the gel was analyzed by Image J for 
quantification. 
Figure 2. Lcn2 expression in transgenic and wild type mice. Lcn2 mRNA was detected by 
real-time PCR and normalized to cyclophilin for each sample. A: transgenic Lcn2 mRNA 
from various tissues. B: total Lcn2 mRNA from various tissues. wt: wild type; tr: 
homozygous transgenic. MG: mammary gland. 
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Table 1 Genetic test for homozygosity 
sex number of pups
F 6 
M 8 
M 12 
F 5 
M 11 
 
PCR identified homozygous transgenic mice were mated with wild type mice. The 
pups were tested for the transgene. All pups were transgenic. 
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